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ABSTRACT
STRUCTURAL AND FUNCTIONAL STUDY OF MULTIDRUG MEMBRANE
TRANSPORTERS
Feng Ding
Old Dominion University, 2013
Director: Dr. Xiao-Hong Nancy Xu

Multidrug membrane transporters (efflux pumps) in both prokaryotes and
eukaryotes are responsible for ineffective treatment of a wide variety of diseases,
including

infections

and

cancer,

underscoring

the

importance

of better

understanding of their structures and functions for design of effective therapies.
Despite extensive studies over decades, their underlying molecular mechanisms
remain largely unknown. In this dissertation, we focus on the study of structures
and functions of multidrug membrane transporters, including ATP-binding
cassette transporter (BmrA) and Resistance-Nodulation-Cell Division transporter
(MexA,B-OprM) in gram-positive and gram-negative bacteria (Bacillus subtilis
and Pseudomonas aeruginosa), respectively. We fused EGFP with N-terminus
and C-terminus of BmrA to construct BmrA-EGFP fusion

proteins and

characterized their efflux functions in four strains of bacterial cells (Ct-BmrAEGFP, Nt-BmrA-EGFP, BmrA and ABmrA, B. subtilis) using fluorescence
microscopy and spectroscopy. The results show that BmrA-EGFP fusion proteins
exhibit the similar efflux kinetics of BmrA and retain the efflux functions of BmrA.
Modeled structures of the fusion proteins show a highly flexible linker region
connecting EGFP with BmrA, suggesting a minimal obstruction of EGFP to
BmrA. These two new strains of BmrA-EGFP offer the possibility for one to

visualize and study efflux function and mechanisms o f BmrA transporters. We
further studied the size-dependent efflux functions of BmrA-EGFP and BmrA
using single plasmonic nanoparticle imaging probes and spectroscopy and found
size-dependent efflux kinetics of BmrA. Using similar approaches, we fused
EGFP with MexA,B-OprM transporters and characterized their efflux functions
using fluorescence spectroscopy and single NP plasmonic spectroscopy. The
results show that EGFP fused MexA,B-OprM only partially retains its original
efflux functions. Structural analysis of fusion protein suggests possible steric
hindrance of EGFP toward the conformation changes of MexA,B-OprM, which
led to the steric effect upon their efflux functions. These important findings offer
new insights into the structural and functional studies of multidrug membrane
transporters

(efflux

pumps),

and

demonstrate

the

powerful

nanobiotechnology for better understanding of multidrug resistance.
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CHAPTER I
OVERVIEW

The phenomena of multidrug resistance (MDR) have been identified in
many types of species ranging from bacterium to human, due to existence of
different types of efflux pumps such as the major facilitator (MF) superfamily, the
small multidrug resistance (SMR) family, the resistance-nodulation-cell division
(RND)

family

and

the

ATP

binding

cassette

(ABC)

superfamily

[1-8].

Overexpression of some ABC pumps often causes the failure of clinical
chemotherapies in many types of human diseases such as cystic fibrosis (CF)
and other cancers [9-11]. Other efflux pumps in the RND family such as MexA.BOprM and MexC,D-OprJ are also found to be responsible for multidrug
resistance in the gram-negative bacteria, Pseudomonas aeruginosa [12-17],
Fluorescent

proteins [e.g.,

cyan

fluorescent protein

(CFP),

green

fluorescent protein (GFP), yellow fluorescent protein (YFP) and red fluorescent
protein (RFP)] have been widely used to study those MDR transporters [18-20].
For example, green fluorescent protein (GFP) has been extensively used as
reporter genes and fluorescence probes to study location, distribution and
functions of proteins in live cells [21-23]. Fluorescent fusion proteins have been
used to label the ABC transporter genes in Caenorhabditis elegans and to
identify the locations of ABC transporters in fission yeast [24].
Compared to conventional fluorescent proteins as described above,
nanometer sized particles such as quantum dots, noble metal nanoparticles

(NPs) (e.g., gold or silver NPs) or magnetic NPs have found their applications in
the area of cancer nanotechnology due to their unique optical, magnetic and
structural properties which are lacking as compared to biological molecules and
bulk materials [25-31]. These properties give them unprecedented advantages
for the diagnosis and treatment of cancer and other human diseases when they
are conjugated with a variety of diagnostic (e.g., optical or magnetic) and
therapeutic (e.g., anticancer drugs or other antibiotics) agents [26, 29, 32-36].
Recent advances are made available in applying NP based probes for molecular
and cellular imaging [37-39], targeted cancer therapy [29, 40] as well as early
screening and detection of cancer [25, 28, 31, 32, 41]. Among those nanometer
sized particles, noble (Ag or Au) NPs have some unique features, such as sizeand shape-dependent optical properties, a high surface area to volume ratio [3739, 42-44]. These optical properties are mainly due to a phenomenon called
localized surface plasmon resonance (LSPR), which is highly dependent upon
their size, shape and surrounding environments. Besides, noble NPs exhibit
strong Rayleigh scattering, allowing them to be directly observed and studied
using dark-field optical microscopy and spectroscopy (DFOMS) systems [37-39,
42-44].

All of these properties have made it possible for them to be very

promising probes for exploring the unknown mechanisms of MDR transporters.
Though extensive studies have been done on the multi-drug resistance
(MDR) transporters over the last two decades, there is still much controversy
regarding the exact efflux mechanisms of many well-studied transporters such as
PgP and MsbA [3, 5, 8, 45-48], Thus, it is still crucial to study their efflux

mechanisms by applying new research tools. The potential outcomes from these
studies will serve as guidance for the development of effective therapeutic agents
for combating those MDR caused diseases.
In this dissertation, I first created two new transgenic strains of Bacillus
subtils (B. subtilis) by fusing EGFP with a ABC transporter called BmrA in grampositive B. subtilis and expressed them in ABmrA strain [22]. Then, we
characterized the efflux functions of those fusion strains by using both traditional
fluorescence probes and novel nanoparticle optical probes. Next, we created and
well characterized the efflux functions of a similar fusion strain by fusing EGFP to
MexB antiporter gene and expressing the fusion gene in AMexB strain of
Pseudomonas aeruginosa (P. aeruginosa), which is gram-negative bacteria and
causes many MDR problems due to the existence of a major RND pump named
MexA,B-OprM. After that, we took a step further by using antibiotics conjugated
nanoparticles as both optical probes and drug carriers to study the toxicity and
biocompatibility of nanoparticle based drug carriers. The obtained outcomes from
those studies enriched our knowledge about the structures and functions of MDR
transporters as well as offered new insights into the future designing of smart
drug carriers to overcome the MDR related problems in terms of increasing
targeting efficacy of therapeutic agents.
This dissertation is comprised of six chapters. In chapter I, we provide a
general overview of the research background related to our studies as well as the
outlines of contents of each chapter.

In Chapter II, in order to study the efflux mechanisms of those MDR
transporters, we first need to light up them. Hence, this Chapter describes the
molecular cloning and characterization of an EGFP fused ABC transporter
(BmrA) in gram-positive Bacillus subtils [22], as illustrated in Fig. 1. We created
two fusion strains by fusing EGFP with both C-terminus and N-terminus of BmrA
gene (Fig. 1-A and B) and successfully expressed the fusion genes in ABmrA
strain. We then characterized the efflux functions of those fusion strains and
compared the results with the ones from using W T and ABmrA strains and
determined that the two new fusion strains maintained the original efflux
functions of BmrA transporter while the strain containing N-terminal fusion of
EGFP with BmrA functions a little better than the other fusion strain.
In Chapter III, from a different perspective, we probed the efflux functions
of the BmrA transporter in different B. subtilis strains including those EGFP fused
BmrA strains by using 12 nm Ag NPs as single nanoparticle optical probes [37],
as illustrated in Fig. 2. Our results indicated that 12nm Ag NPs are the substrates
of this BmrA efflux pump. Besides, different strains showed different efflux
kinetics of 12 nm Ag NPs. More specifically, we found ABmrA strain accumulated
more intracellular NPs over time than WT or the two fusion strain did due to the
lacking of BmrA transporter. Those results clearly suggested that the Ag NPs
could also be the substrates of those MDR transporters, which makes it possible
for us to use them to probe the efflux function kinetics over time owing to their
unique physical and chemical properties.

In Chapters IV, to compare with the EGFP fused BmrA transporter in
gram-positive Bacillus subtilis (Chapter II), we fused EGFP to the MexB part of
MexA,B-OprM transporter in gram-negative Pseudomonas aeruginosa and well
characterized the efflux functions of this new fusion strain, as illustrated in Fig. 3.
Our results indicated that EGFP fused MexB antiporter only retained partial efflux
functions of MexA,B-OprM efflux pump, which suggest possible steric hindrance
effects resulting from either the fusion of EGFP with MexB or the assembly of a
dysfunctional MexA,B-OprM efflux pump which contains three copies of each
component of this efflux pump (MexA, MexB and OprM) on the inner and outer
membranes of P. aeruginosa bacteria.
In Chapter V, in order to study the biocompatibility and toxicity of NPs as
effective drug carriers, we conjugated silver NPs with the antibiotic (ofloxacin)
and compared the size-dependent antibacterial effects of ofloxacin alone
(absence of NPs) and various sized silver NPs conjugated ofloxacin in
Pseudomonas aeruginosa, as illustrated in Fig. 4. Our results indicated that
larger sized nano-carriers generated more potent antibacterial effects compared
to smaller sized nano-carriers when the total amount of antibiotic molecules
contained in all sized nano-carriers is the same. Those interesting results offered
new insights into the future design of efficient drug carriers in the process of
combating the MDR caused diseases.
In Chapter VI, we summarized our major research findings in those
preceding chapters (Chapter ll-V).
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Fig. 1 Illustration of design and characterization of efflux functions of ABCEGFP transporters in gram-positive Bacillus subtilis.
We fused EGFP to both C-terminus and N-terminus of BmrA gene and
expressed fusion genes in ABmrA strain. Efflux functions of fusion strains were
characterized by time course incorporation of fluorescence dye molecules and
results suggested that both fusion strains maintained the original efflux functions
of BmrA transporter. Modeling prediction of both fusion proteins indicated no
steric hindrances effects of EGFP to BmrA protein. The individual BmrA
monomers (light orange or yellow), AMP-PNP (red-white-blue spheres), and
EGFP (green) are illustrated, respectively [22]
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Fig. 2 Illustration of transport of silver NPs across the cell membrane by a
ABC transporter (BmrA) in gram-positive Bacillus subtilis.
We probed the efflux functions of different B. subtilis strains with different
expression level of BmrA proteins by transport of Ag NPs based single plasmonic
optical probes across the cell membrane. Results indicated that accumulation
and efflux kinetics of intracellular NPs for single living cells depended upon the
cellular expression level of BmrA, NP concentrations, and a pump inhibitor
(orthovanadate), suggesting that NPs are substrates o f BmrA transporters and
the passive diffusion driven by concentration gradients is the primary mechanism
for NPs to enter the cells. The functional BmrA transporter is illustrated as
combination of two BmrA monomers with each monomer containing a nucleotide
binding domain (A) and a transmembrane domain (T). Ag NPs are illustrated as
blue, green, yellow and red spheres [37]
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EG FP Nt-fuaon protein
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Fig. 3 Illustration o f design and characterization o f efflux fun ctio n s o f RNDEGFP transporters in gram-negative Pseudom onas aeruginosa.
We fused EGFP to N-terminus of mexB gene and expressed the fusion gene in
AMexB strain. Efflux functions of fusion strains were characterized by both time
course incorporation of fluorescence dye molecules and measurement of MICs of
selected antibiotics. Results suggested that the fusion strain partially retained the
original efflux functions of MexA,B-OprM transporter. Modeling prediction of the
fusion protein indicated possible steric hindrances effects of EGFP fused to
MexB, which may lead to dysfunctional assembly of MexA.B-OprM transporter
across the cell membrane. The membrane fusion protein MexA (turquoise), outer
membrane channel OprM (violet), the individual antiporter MexB monomers (red,
orange, and light brown) and EGFP (green) are illustrated, respectively [8]
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Fig. 4 Illustration of study of size-dependent antimicrobial effects of nano
carriers on gram-negative bacteria, Pseudomonas aeruginosa.
We synthesized and characterized three sized Ag NPs conjugated with drug
molecules and we studied the antimicrobial effects of these nano-carriers on the
growth of bacteria in P. aeruginosa. We found the size-dependent inhibitory
effects of these nano-carriers on the growth of bacteria, with larger nano-carriers
conferring

higher antimicrobial

effects than

smaller ones

at the

same

concentration of conjugated drug molecules on their surfaces. Ag NPs of different
sizes (2.4, 13.0 and 92.6 nm) are illustrated as blue, green and red spheres,
respectively. Molecular structure of ofloxacin is shown above and ofloxacin in
different sized Ag carriers is represented by 4-point star ( ^ )

CHAPTER II
DESIGN AND PROBING OF EFFLUX FUNCTIONS OF EGFP FUSED
ABC MEMBRANE TRANSPORTERS IN GRAM-POSITIVE BACTERIAL
CELLS USING FLUORESCENCE SPECTROSCOPY

INTRODUCTION
ABC (ATP-binding cassette) transporters exist in all live organisms,
ranging from bacteria to human [1, 49-53]. They are involved in the unidirectional
transport, either import or export, of a wide variety of structurally and functionally
unrelated substrates, including ions, sugars, lipids, amino-acids, proteins, or
xenobiotics, against substrate concentration gradients [1, 49-54]. Such function is
responsible for multidrug resistance (MDR) in bacteria and cancer cells. In
bacteria, ABC transporters constitute the largest protein family. For instance, 78
ABC transporters have been reported in B. subtilis [55, 56]. Notably, 48 ABC
transporters have been identified in human. Abnormal functioning of some of
these ABC transporters in human is directly responsible for severe pathologies
[10]. For example,

P-glycoprotein, the first mammalian ABC transporter

identified, accounts for MDR in cancer cells, which leads to ineffective therapy.
Cystic fibrosis is caused by mutations in the chloride channel of cystic fibrosis
transmembrane regulator [9-11],
Interestingly, all ABC transporters share a common organization, which
consists of four core domains: two transmembrane domains (TMD) and two
nucleotide-binding domains (NBD) [46, 52, 57-61]. The TMDs are quite variable
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in sequence and topology, which defines the substrate binding sites and forms
the transport passageway for substrates to cross the membrane. In contrast, the
NBDs show conserved sequences, which empower the transporters by binding
and hydrolyzing ATP [46, 57, 61, 62]. These four domains are either fused as a
single polypeptide or present in two to four separate polypeptides. Threedimensional (3D) structures of many NBDs isolated from various origins share
the same global topology, suggesting a common evolutionary origin and similar
mechanisms of energy coupling in all ABC transporters [52,62],
Despite extensive studies, their translocation mechanisms remain elusive
[9, 52].

Many fundamental questions about molecular mechanisms and

interactions of multidrug ABC transporters (efflux pumps) remain unanswered [9,
52, 62]. For example, one major question is how to identify the individual
integrated steps of the catalytic cycle, which are responsible for substrate
translocation. Notably, fusion of ABC membrane transporters with EGFP offers
the opportunity to visualize membrane transporters and to study their interactions
with substrates that lead to their translocations. However, the fusion of ABC
transporters with EGFP may alter their efflux function. Thus, it is crucial to first
characterize the efflux function of ABC-EGFP transporters, prior to using them to
probe their molecular mechanisms.
Fluorescent proteins (e.g., GFP) have been widely used as reporter genes
and non-invasive fluorescence probes for study of molecular mechanisms and
functions of proteins in live cells [20, 63]. Promoter-fluorescent protein fusions
have been used to identify the ABC transporter genes in Caenorhabditis e/egans
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and to determine the locations of ABC transporters in fission yeast [24, 64]. GFP
has been used as a fluorescence probe to characterize the topologies of ABC
transporters, because GFP fluoresces in the cytoplasmic space (reducing
environment), but not in the periplasm or plasma membrane [65, 66], Studies
have shown that GFP fusion proteins (membrane transporters) may alter the
function of proteins [67, 66]. Unfortunately, the functions of GFP fused proteins
(transporters) have not yet been widely characterized and compared with the
non-fused proteins.
Currently, structures o f membrane transporters are characterized by X-ray
crystallography, which is limited by the difficulties of crystallization of membrane
proteins. It is also unable to provide real-time kinetic information about the
molecular mechanisms and conformation change of ABC transporters.
The primary methods for study of multidrug membrane transporters in
bacterial and mammalian cells include the measurement of their accumulation of
radioactively labeled substrates (14C and 3H) and the fluorescence dyes (e.g.,
rhodamine 123, Fluo-3, Hoechst dyes) [54, 68-76]. Fluorescent dyes, such as
Hoechst dyes and ethidium bromide (EtBr), emit weak fluorescence in aqueous
solution (outside cells) and become strongly fluorescent in non-polar and
hydrophobic environments, especially as the dye molecules enter cells and
intercalate with DNA [77]. Thus, time-dependent (time-course) fluorescence
intensity of the dyes is particularly suitable for real-time monitoring of the
accumulation of substrates in bacterial and mammalian cells and for study of
multidrug transporters in live cells [54, 68-76].
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Efflux function of multidrug membrane transporters has also been
characterized by determining the minimal inhibitory concentrations (MICs) of
drugs (e.g., antibiotics) that are specific substrates of the transporters and show
the specific susceptibility toward given strains of bacterial cells [78, 79].
Unfortunately, to our knowledge, antibiotics that are specific substrates of BmrA
membrane transporter and show specific susceptibility for BmrA cells, but not
ABmrA cells, have not yet been identified. Thus, MIC method has not yet been
used to characterize BmrA transporter.
In this study, we constructed two fusion proteins by fusing either C- or Nterminal BmrA gene with EGFP vectors, and expressing them in ABmrA cells to
produce two new strains of B. subtilis. To determine whether BmrA-EGFP
transporters retain the efflux function of BmrA, we characterized their efflux
kinetics of fluorescence molecules (Hoechst 33342), and their dependence on
the expression of BmrA and the presence of a pump inhibitor (orthovanadate)
using fluorescence spectroscopy. To our knowledge, BmrA-EGFP transporters in
B. subtilis have not yet been reported. These new strains are needed for study of
functions and structures of BmrA transporter in single live cells.

RESULTS AND DISCUSSION
Construction and characterization of BmrA-EGFP fusion genes and their
expression
We designed and constructed bmrA-EGFP fusion genes by fusing the Cterminal or N-terminal bmrA genes with EGFP vectors. The fusion genes,

pSG1154-BmrA (54A) and pSG1729-BmrA (29A), were constructed as shown in
Fig. 5 and as described in Experimental Section. The pET23-BmrA plasmid was
amplified using two sets of primers, C-terminal (CP1, CP2) or N-terminal (NP1,
NP2) primers, via PCR. The amplified PCR products and vectors (pSG1154 and
pSG1729) were then digested using a pair of restriction endonuclease enzymes
(XhoUEcoRl). The digested and purified PRC products (1800 base pairs, bp,
bmrA genes) were finally ligated with the digested and purified vectors (7600 bp),
pSG1154 or pSG1729, respectively. This approach enables us to insert the bmrA
gene into each vector via fusion of C-terminal or N-terminal bmrA genes with
EGFP gene, and to create two fusion genes (pSG1154-BmrA and pSG1729BmrA), respectively.
The amplified PCR products in Fig. 5 were characterized using gel
electrophoresis and DNA sequencing. The results in Fig. 6A show that both PCR
products of pET23-BmrA plasmid amplified by using C-terminal and N-terminal
primers are 1, 800 bp, which agrees well with the number of base pair of the
bmrA gene [80]. The fusion genes digested by a pair of restriction endonuclease
enzymes (Xho\ / EcoRI) (Fig. 6B) show the products of 7, 600 bp and 1, 800 bp,
which agree well with that of digested vectors and bmrA genes [18, 80],
respectively. The DNA sequencing results (sequence data not shown) of both
fusion genes show that the sequences of bmrA gene are in excellent agreement
with those reported previously [18, 80],
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Fig. 5 Schematic illustrations of construction of (A) Ct-bmrA-EGFP and (B)
Nt-bmrA-EGFP fusion genes.
The plasmid (pET23-BmrA) was amplified using two pairs of primers (CP1 and
CP2, or NP1 and NP2) by PCR, respectively. The amplified genes and vectors
(pSG1154 or pSG1729) were digested by restriction enzymes (Xhol/ EcoRl). The
digested genes were ligated to the digested vectors, generating pSG1154-BmrA
(54A, Ct-bmrA-EGFP’) and pSG1729-BmrA (29A, Nt-bmrA-EGFP) fusion genes,
respectively
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Fig. 6 Characterization of bmrA-EGFP fusion genes using agarose gel
electrophoresis.
(A) L1: DNA markers/ladders in base pair (bp); L2: bmrA gene amplified using
the plasmid (pET23-BmrA) as a template and CP1 or CP2 as primers (PCR
Product I in Fig. 5); L3: bmrA gene amplified using the plasmid (pET23-BmrA) as
a template and NP1 or NP2 as primers (PCR Product II in Fig. 5). Arrows point to
the PCR products of 1,800 bp, which agrees with the number of base pairs of
bmrA genes. (B) L1: DNA markers in bp; L2: pSG1729-BmrA; L3: pSG1154BmrA; L4: pSG1729, and L5: pSG1154, digested by Xhol/EcoR, respectively.
Arrows point to the digested vector plasmids at 7,600 bp and bmrA genes at
1,800 bp

Fig. 7 Characterization of expression of bmrA-EGFP fusion genes in
ABmrA cells.
(A) Dark-field optical images and (B) green fluorescence images of single live
cells: (a) Nt-BmrA-EGFP; (b) Ct-BmrAEGFP; (c) WT-BmrA; and (d) ABmrA
strains, respectively. The intensity scales are 55-355 ADC (analog and digital
counts) in (A) and 55-95 ADC in (B) Scale bar = 5 pm

We transformed the fusion gene (pSG1154-BmrA or pSG1729-BmrA) into
ABmrA cells to create two new strains of B. subtilis (Ct-BmrA-EGFP and NtBmrA-EGFP cells). Their expression in single live cells was characterized by
measuring fluorescence of EGFP in single live cells using fluorescence
microscopy and spectroscopy. The results in Fig. 7 show that all Ct-BmrA-EGFP
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and Nt-BmrA-EGFP cells, but none of BmrA and ABmrA cells, emit green
fluorescence, which demonstrates the successful expression of fusion genes in
the cells.
Notably, these two new strains offer the possibility of characterization of
locations, topologies and functions of BmrA membrane transporters in live cells,
as those reported for other ABC transporters [65-67, 81]. For instance, fusion of
EGFP with BmrA enables one to probe the locations and topologies of BmrA and
the translocation of pump substrates (efflux function) of BmrA in live cells in real
time. However, BmrA-EGFP transporters must first be characterized to determine
whether they retain the original efflux functions of BmrA, prior to their uses for
study of functions and structures of BmrA.

Study of suitability of fluorescence molecules for probing of efflux kinetics
of transporters in live cells
Hoechst dyes are well known substrates of ABC membrane transporters
and have been used to monitor the accumulation and efflux kinetics of the BmrA
transporter embedded in vesicles [54, 76]. Notably, Hoechst molecules emit
week fluorescence in aqueous solution (outside the cells), and their fluorescence
intensity increases substantially (up to 10-fold), as they enter into the cells and
intercalate with DNA [77], Thus, the fluorescence intensity of the dye molecules
can be used to measure the accumulation and efflux kinetics of membrane
transporters in live cells in real time.

To determine whether time-dependent fluorescence intensity of the dye
molecules acquired at the peak wavelength (Amax) of 450 nm is suitable for
monitoring their accumulation kinetics in live cells in real time, we acquired the
fluorescence spectra of the dye molecules incubated with the live cells (Ct-BmrAEGFP, Nt-BmrA-EGFP, WT, ABmrA cells) over time. The representative results
in Fig. 8A show that the Amax of its emission spectra at 450 nm remains
essentially unchanged over time, and its fluorescence intensity increases with
time. The results show that intercalation of dye molecules with intracellular DNA
in live cells did not lead to the shift of Amax of their excitation and emission
spectra, and the presence of EGFP did not affect fluorescence measurements of
the dye molecules.
To determine whether photodecomposition of the dye molecules could
significantly affect their fluorescence intensity over time, we measured the
excitation and emission spectra of the dye molecules incubated with the live cells
that had been constantly irradiated by the excitation beam (350 nm) or kept in the
dark for 30 min. The results in Fig. 8B show that the fluorescence intensity and
Amax of the excitation and emission spectra for the exposed and unexposed
samples are nearly identical.
Taken together, the results in Fig. 8 show that the time-dependent
fluorescence intensity of the dye molecules incubated with live cells at 450 nm is
well suited for monitoring of their accumulation kinetics in live cells using
fluorescence spectroscopy. By probing of dependence of their accumulation
kinetics on the expression level of BmrA in each strain, we can characterize the
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efflux function of BmrA and BmrA-EGFP transporters in live cells and determine
whether BmrA-EGFP retains the efflux function of BmrA.

Probing

of dependence of efflux

kinetics of transporters

on their

expression in live cells
To determine whether BmrA-EGFP proteins expressed in ABmrA cells
retain the efflux function of BmrA transporter, we studied the efflux kinetics of
membrane transporters in live cells in real time using the fluorescence probe
(Hoechst 33342). The studies were performed in the absence and presence of
glucose, aiming to determine the roles of glucose on the efflux function of BmrA
in live cells. It is worthy noting that previous studies for probing o f accumulation
and efflux kinetics of the dye molecules for ABC transporters were carried out in
the presence of glucose [54, 76]. Notably, the potential effects of the glucose on
the accumulation and efflux function of ABC transporters were not studied.
The results in Fig. 9A show that, in the absence of glucose, the
fluorescence intensity of the dye molecules increases with time, indicating that
the dye molecules enter the cells and intercalate with intracellular DNA. Notably,
the accumulation rates (slope of the each curve) highly depend upon the
expression level of BmrA in the cells. ABmrA cells (deletion of BmrA) show the
highest accumulation rates with the highest fluorescence intensity at each given
equilibrium time, while WT-BmrA cells (normal expression of BmrA) exhibit the
lowest rates.
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molecules for probing the efflux kinetics of BmrA and BmrA-EGFP
membrane transporters in live cells (Ct-BmrA-EGFP or Nt-BmrA-EGFP).
(A) Fluorescence emission spectra of the dye molecules (2 pM) incubated with
the cells

( O D 6oonm

= 0.1) at (a) 5, (b) 200, and (c) 400 s, show that the peak

wavelength of the spectra (Amax = 450 nm) remains essentially unchanged, while
fluorescence intensity increases with time. (B) Excitation and emission spectra of
the dye molecules (2 pM) incubated with the cells that: (a) and (b) had been
exposed to 350 nm excitation beam for 30 min; and (c) and (d) in the dark, show
that the fluorescence intensity and Amax of the spectra of both samples are nearly
identical
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Both Nt-BmrA-EGFP and Ct-BmrA-EGFP cells (over expression of BmrA)
show the lower accumulation rates than ABmrA, suggesting that both BmrAEGFP cells extrude the intracellular dye molecules which lead to the lower
accumulation

rates.

Notably,

Nt-BmrA-EGFP

cells

have

slightly

higher

accumulation rates than BmrA cells, but much lower accumulation rates than CtBmrA-EGFP cells. The results suggest that fusion of either N-terminal or Cterminal BmrA with EGFP retains efflux function of BmrA, with less steric effect of
EGFP on N-terminal fusion.
In the presence of glucose (Fig. 9B), ABmrA cells display the highest
accumulation rates with the highest intracellular dye molecules, both Ct-BmrAEGFP and Nt-BmrA-EGFP cells show the lowest rates with the lowest amount of
the intracellular dye molecule. Interestingly, the BmrA cells show higher
accumulation rates with higher amount of intracellular dye molecules than BmrAEGFP cells. The results show that the presence of glucose leads to three orders
of magnitude higher accumulation rates and higher amount of intracellular dye
molecules in a shorter period of time than the absence of glucose. The
quantitative results of Fig. 9 are summarized in Table 1.
Taken together, the results in Fig. 9 indicate that the presence of glucose
affects the study of the efflux function of BmrA and BmrA-EGFP transporters
using the dye molecules via fluorescence spectroscopy. The results suggest
drastic effects of glucose upon the accumulation and efflux of the dye molecules
by live cells. Further studies are underway to determine the roles of glucose in
accumulation and efflux function of BmrA transporters.
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Fig. 9 Study of the dependence of accumulation and efflux kinetics of the
intracellular dye molecules on the expression of BmrA and BmrA-EGFP
transporters in live cells.
Time-dependent fluorescence intensity of the dye molecules (2 pM) incubated
with cells

(O D e o o n m

= 0.1): (a) ABmrA, (b) Ct-BmrA-EGFP, (c) W T (BmrA), and

(d) Nt-BmrA-EGFP strains, in (A) absence and (B) presence of 25 mM glucose
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Inhibitory effects of a pump inhibitor on efflux kinetics of transporters in
live cells
To determine whether BmrA and BmrA-EGFP membrane transporters are
specifically responsible for the efflux of the dye molecules out of the cells, we
studied the accumulation kinetics of the intracellular dye molecules in live cells
(WT BmrA, Nt-BmrA-EGFP, Ct-BmrA-EGFP, ABmrA cells) in the presence of a
pump

(ATPase)

inhibitor,

orthovanadate

[82,

83],

using

fluorescence

spectroscopy.
The results in Fig. 10a show, in the absence of the glucose, the lower
accumulation rates and the lower amount of the intracellular dye molecules were
found in the cells (WT, Nt-BmrA-EGFP, Ct-BmrA-EGFP strain) in the absence of
orthovanadate (Fig. 10A-C, a, i) than its presence (Fig. 10A-C, a, ii), respectively.
In contrast, the accumulation rates and amount of the intracellular dye molecules
for ABmrA cells remain nearly unchanged in the absence (Fig. 10D, a, i) and the
presence of the orthovanadate (Fig. 10D, a, ii). This experiment serves as a
control, which demonstrates that orthovanadate at the given dose used in this
study specifically inhibits the efflux function o f BmrA transporter, but not other
membrane transporters in the cells.
These results show the inhibitory effects of the pump inhibitor on the efflux
function of BmrA and BmrA-EGFP, suggesting that BmrA and BmrA-EGFP
transporters are indeed responsible for the extrusion of the dye molecules out of
the cells, which lead to the lower accumulation rates than ABmrA. Interestingly,
the less inhibitory effects of orthovanadate on efflux of the dye molecules by Nt-
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BmrA-EGFP than Ct-BmrA-EGFP (Fig. 10B-C, a) were observed. The plausible
explanation may be that either high amount of orthovanadate are needed to
inhibit the efflux function of Nt-BmrA-EGFP or the N-terminal fusion is less
sensitive to the inhibitory effect of orthovanadate than C-terminal fusion. Further
studies are needed to depict the detailed mechanisms.
Interestingly, in the presence of glucose, the accumulation rates of the dye
molecules and their accumulation amount in all four strains remain essentially
unchanged in the presence and absence of orthovanadate, as shown in Fig. 10b,
respectively.
Notably, the accumulation rates of the intracellular dye molecules are
much lower in the absence of glucose (Fig. 10a) than its presence (Fig. 10b).
The quantitative analysis of accumulation rates in Fig. 10 are summarized in
Table 1. The results suggest that the effects of glucose on the accumulation and
efflux of the dye molecules in live cells are higher than the inhibitory effects of
orthovanadate. Thus, in the presence of glucose, we observed no inhibitory
effects of orthovanadate.
Taken together, these results (Fig. 10) show the inhibitory effect of
orthovanadate upon efflux function of BmrA and BmrA-EGFP transporters and
suggest that they are responsible for efflux of the dye molecules out of the cells.
Thus, BmrA-EGFP retains the efflux function of the BmrA. The results also show
the drastic effects of glucose upon the efflux of intracellular dye molecules by the
transporters in live cells, suggesting that efflux function of ABC transporters must
be characterized in the absence of glucose.

26
Table 1 Summary of accumulation rates of dye molecules in live cells

C glucose

Inhibitor*

(mM)

(pM)

Accumulation Rateb (1/s)

WT

Ctc

Ntd

ABmrA

0

0

3.8 x10 3

1.1 x10'2

5.1 xIO"’*

3.1 x102

0

25

2.2 x10 2

2.5x1 O'2

1.6 x10'2

3.1 x1 O'2

25

0

1.1

0.6

0.5

1.0

25

25

1.1

0.7

0.8

1.4

a Orthovanadate
b Rate = slopes of the curves at its half equilibrium time. The equilibrium time is
defined at the time that the fluorescence intensity reaches the maximum and
remains essentially unchanged.
c Ct-BmrA-EGFP: cells with the over-expression of C-terminal BmrA fused with
EGFP
d Nt-BmrA-EGFP: cells with the over-expression of N-terminal BmrA fused with
EGFP

Structural Modeling and Analysis of Fusion BmrA-EGFP Transporters
The results in Figs. 9A and 10a show that Ct-BmrA-EGFP and Nt-BmrAEGFP transporters extrude the intracellular dye molecules and their efflux
function is inhibited by the ABC (ATPase) inhibitor (orthovanadate), suggesting
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Fig. 10 Probing of inhibitory effects of a pump inhibitor (orthovanadate) on
efflux function of BmrA and BmrA-EGFP transporters.
Time-dependent fluorescence (FL) intensity of the dye molecules (2 pM)
incubated with the cells (ODeoonm = 0.1): (A) W T (BmrA), (B) Ct-BmrA-EGFP, (C)
Nt-BmrA-EGFP, and (D) ABmrA, in (a) absence and (b) presence of glucose (25
mM) and (i) without and (ii) with orthovanadate (25 pM). Note that the initial
fluorescence intensity in Fig. 10D-a varies slightly, which is attributed to the slight
variation of cell concentrations
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that the fusion proteins retain efflux function o f BmrA. The results show that NtBmrA-EGFP transporter exhibits the higher efflux rates (lower accumulation
rates) than Ct-BmrA-EGFP, indicating that EGFP contributes less hindrance to
the efflux function of Nt-BmrA-EGFP than Ct-BmrA-EGFP transporter.
To better understand these interesting findings, we modeled Ct-BmrAEGFP and Nt-BmrA-EGFP, as described in experimental and model section. We
used SWISS-MODEL to assemble EGPF and BmrA models using available 3D
structures of GFP (PDB-code: 3ogo) with a sequence identity of 98.7%; and
homologous structural models of the ‘closed’ multidrug ABC transporter Sav1866
and LmrA with up to 33.7 % sequence identity (PDB-codes: 2onj, 2hyd, 1mv5)
[84, 85], respectively. The secondary structures of the truncated regions
connecting the EGFP to BmrA were analyzed by PSIPRED server [86].
results (Fig.

The

11A-B) show that the linker regions are unstructured and

conformationally flexible.
The model of Ct-BmrA-EGFP dimer in Fig. 11C shows that the EGFP
situates at the top of the ATP-binding domain (NBD) of the BmrA transporter. In
contrast, the model of Nt-BmrA-EGFP dimer in Fig. 11D depicts that the EGFP
protrudes sideways from the TMDs. We observed fluorescence of EGFP for both
fusion strains, indicating that the EGFP was located in the cytoplasm, but not in
the cellular plasma membrane (next to the TMD). Studies have shown that, in
contrast to cellular plasma membranes, the cytoplasmic space offers the required
reducing conditions, which enable the EGFP to fluoresce [65].
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EGFP dimer model shows the EGFP domains on the top of the ATP-binding
domains (NBDs). (D) Nt-BmrA-EGFP dimmer model shows the EGFP domains
protruding sidewards of transmembrane domains (TMDs). The individual BmrA
monomers in light orange or yellow, AMPPNP in red-white-blue spheres, and
EGFP in green are illustrated

Both structures show that the EGFP is linked to BmrA via a long
unstructured loop region comprised of 19 amino acids for the Ct-BmrA-EGFP
and 23 amino acids for the Nt-BmrA-EGFP, respectively. Such highly flexible
linker regions allow substantial mobility of the EGFP molecule in the positional
placement in relation to the BmrA transporter. Thus, EGFP does not create
significant obstruction to the BmrA in either fusion proteins. Nonetheless, the
structure of Ct-BmrA-EGFP dimer (Fig. 11C) shows the closer proximity (-1 4 A)
of two C-termini of BmrA in the “closed” dimer. Thereby, it may result in
additional interference of EGFP with the function of BmrA, as BmrA converts
from the ‘open’ to the ‘closed’ conformation during the substrate transport cycle.
In contrast, the structure of Nt-BmrA-EGFP dimer (Fig. 11D) illustrates that the
distance between two N-termini of BmrA in the “closed” dimer is 47.9 A, which is
larger than that of C-terminal fusion, suggesting less interference of N-terminal
fusion of BmrA with EGFP.
Taken together, this structural analysis provides interesting evidence to
explain why Ct-BmrA-EGFP and Nt-BmrA-EGFP transporters retain the efflux
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function of BmrA, and why Nt-BmrA-EGFP is more favorable for the efflux
substrate translocation than Ct-BmrA-EGFP.

SUMMARY
In summary, we have designed and constructed bmrA-EGFP fusion genes
and successfully expressed them in ABmrA cells to generate two new strains of
B. subtilis (Ct-BmrA-EGFP and Nt-BmrA-EGFP). We studied the dependence of
accumulation kinetics of intracellular fluorescence molecules (Hoechst 33342, a
pump substrate) on the expression level of BmrA and BmrA-EGFP transporters
for each strain (WT, ABmrA, Ct-BmrA-EGFP, Nt-BmrA-EGFP), by measuring the
time-dependent fluorescence intensity of the intracellular dye molecules using
fluorescence spectroscopy. We found that either Ct-BmrA-EGFP or Nt-BmrAEGFP extruded the pump substrate, leading to the lower accumulation of the
intracellular dye molecules than ABmrA. The results suggest that the fusion
proteins retain the efflux function of BmrA. Notably, Nt-BmrA-EGFP extruded the
intracellular dye molecules more rapidly than Ct-BmrA-EGFP. Our structural
analysis shows the highly flexible linker regions connecting EGFP with BmrA in
the fusion proteins, suggesting a minimal obstruction of EGFP to the BmrA.
Nonetheless, two C-termini of the “close” dimer of BmrA is in closer proximity (14
A) than two N-termini of the dimer (47.9 A), which suggests the less steric effect
of the N-terminal BmrA fusion on its efflux function than the C-terminal fusion.
The efflux function of both BmrA-EGFP transporters was inhibited by the ABC
pump inhibitor (orthovanadate), which further demonstrated that both fusion
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pumps retain the efflux function of BmrA transporter. This study also shows that
the presence of glucose affects the accumulation and efflux of the dye molecules
by the transporters in live cells using fluorescence spectroscopy. Thus, the efflux
function of ABC transporters must be characterized in the absence of glucose.

METHODS
Reagents and cell strains
Escherichia

coli

DH5a

(Invitrogen),

PCR

polymerase

(Agilent

Technologies), plasmid isolation kit (Qiagen), DNA gel extraction kit (Qiagen),
DNA ligation kit (T4 DNA ligase and ligation buffer) (Roche), XhoUEcoRl (NEB),
tetracycline

(Calbiochem),

spectinomycin

(Enzo),

xylose

(Spectrum),

orthovanadate (Sigma), Hoechst 33342 (Invitrogen), casamino acid (BD),
tryptose blood agar base powder (BD), B. subtilis strain (1A772, WT BmrA) and
plasmids (pSG1154 and pSG1729) from Bacillus Genome Stock Center (BGSC)
[18], were purchased and used as received. ABmrA and plasmid (pET23-bmrA)
were provided by J. M. Jault [54].
All other media and cell culture plates were prepared in our lab. Medium A
(100 mL) was prepared by mixing 10x Medium A base (10 mL) and 10x Bacillus
salts (9 mL) in the sterilized Dl water. Medium B were prepared by mixing
Medium A (10 mL), CaCI2 (0.1 mL, 50 mM) and MgCI2 (0.1 mL, 0.25 mM). The
10x Media A base (1 L) was prepared by mixing yeast extract (10 g), casamino
acids (2 g) and glucose (100 mL, 50%) in Dl water. The 10x Bacillus salts (1 L)
was prepared by dissolving (NH4 )2 SQ4 (20 g), K2H P 04-3H20 (183 g), KH2PQ4
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(60 g), sodium citrate (10 g), and M gS04-7H20 (2 g) in Dl water. The tryptose
blood agar base plate was prepared by mixing tryptose blood agar base powder
(3.3 g) in Dl water (100 ml_), which was then autoclaved, cooled to 45-50 °C, and
mixed with sterile defibrinated blood (50 ml_). The mixture was immediately used
to prepare the plates.

Cell culture and assay
Four B. subtilis strains (WT-BmrA, Ct-BmrA-EGFP, Nt-BmrA-EGFP, and
ABmrA cells) were pre-cultured by inoculating single clones of each strain from
the tryptose blood agar plates into each flask containing LB medium (1%
tryptone, 0.5% yeast extract and 0.5% NaCI, pH 7.2). The flasks were placed in a
shaker (LabLine Orbit-Environ, 37°C, 150 rpm) for 12 h. The cells were then
cultured in the medium for another 8 h, WT and ABmrA in LB medium and CtBmrA-EGFP and Nt-BmrA-EGFP cells in LB medium with 1% xylose. The
cultured cells were harvested and washed three times with PBS buffer using
centrifugation (Beckman J2-21, JA-14, 6000 rpm). The washed cells resuspended in the buffer (ODeoonm = 0.1) were used to study the accumulation
kinetics of the fluorescence dye (Hoechst 33342) in the cells using fluorescence
spectroscopy.

Construction and characterization of bmrA-EGFP fusion genes
We fused C-terminal bmrA gene with N-terminus EGFP (pSG1154) or Nterminal bmrA gene with C-terminus EGFP (pSG1729) in each vector to
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construct two fusion genes, Ct-bmrA-EGFP (pSG1154-BmrA) and Nt-bmrAEGFP (pSG1729-BmrA) genes (Fig. 5), respectively. We named them as 54A
and 29A, respectively.
The pET23-BmrA plasmid was used as a template, and two pairs of
primers (CP1 and CP2 or NP1 and NP2) were used to amplify the bmrA gene
using PCR to generate PCR product I and II (Fig. 6). The sequences of the
primers are CP1 (5’-GCG CGC TCG AGG GAG GAA AAT ATA TGC CAA CCA
AGA AAC AAA-3’); CP2 (5’-GCG CGG AAT TCC CCG GCT TTG TTT TCT
AAG-3’); NP1 (5 - GCG CGC TCG AGA TGC CAA CCA AGA AAC AAA-3’); and
NP2 (5-GCG CGG AAT TCT TAC CCG GCT TTG TTT-3’).
Each PCR product and vector (pSG1154 or pSG1729) was digested by a
pair of restriction enzymes (XhoMEcoR\) by incubating the PCR product (10 ng)
or the vector (5 ng), with two units of Xho\/EcoR\, in the digestion buffer (40 or 30
pL) at 37 °C for 3 h. The digested products were characterized using agarose gel
electrophoresis (0.8%, 8-10 V/cm) and purified using the gel extraction kit. The
digested and purified PCR product I or II (20 nM) were ligated into the digested
and purified vector (pSG1154 or pSG1729, 5 nM) in T4 DNA ligase (one unit in
20 pL ligation buffer) at 12 °C overnight, respectively,
Each ligated product was transformed into DH5a competent cells
(Invitrogen), as described previously [87, 88], Briefly, the ligated solution (10 pL)
with the competent cell suspension (100 pL, ~2x107cells/ml_) was mixed and
placed on ice for 30 min. The mixture was heated at 42 °C for 90 s and then
placed on the ice for another 2 min. The LB media (1 mL) was added into the
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mixture, which was incubated in the shaker (37 °C, 150 rpm) for 1 h.
Transformed cells were then harvested using centrifugation and suspended in
the fresh medium, which was then inoculated onto LB plates and incubated at 37
°C for 24 hours.
The clones from each plate were inoculated into the LB medium (3 mL)
containing 100 pg/mL ampicillin and cultured in the shaker (150 rpm, 37 °C) for
24 h. The plasmid (fusion genes) of each clone was isolated and amplified by
PCR. The amplified PCR products were characterized using the restriction
enzymes (XhoUEcoR\), gel electrophoresis, and DNA sequencing (Applied
Biosystem, 3730x1 DNA Analyzer), to verify successful construction of fusion
genes.

Characterization of expression of fusion genes in single live cells
Each characterized fusion plasmid was transformed into ABmrA cells
using a previously reported protocol [87, 88], Briefly, the ABmrA cell plates were
prepared by inoculating the cells onto the tryptose blood agar base plates and
incubating them at 37 °C overnight. The clones on the plates were inoculated into
Medium A (4.5 mL). The cell suspension (ODesonm = 0.1) was incubated in the
shaker (37 °C, 150 rpm) for 3 h. The cell growth was followed over time. The
number of the cells increased with time slowly for 40 min, then logarithmically for
50 min and slowly again for another 90 min.
By then, the cell suspension (50 pL) was transferred into pre-warmed
Medium B (0.45 mL) and cultured in the shaker (37 °C, 150 rpm) for 90 min. The
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fusion plasmid (pSG1154-bmrA or pSG1729-bmrA, 1 pg) was then added into
the cell suspension and incubated in the shaker (37 °C, 150 rpm) for 30 min.
Each aliquot of the transformants (200 pL for each plate) was spread onto the LB
agar plate and incubated at 37 °C for 24 h. The clones were picked and cultured,
as described above.
The starch-iodine assay was used to confirm the insertions of bmrA-EGFP
fusion genes into the chromosome via double crossover events at the amyE site,
as described in the following. Transformants were patched onto the LB agar
plates containing 1% (w/v) starch, tetracycline (5 pg/mL) and spectinomycin (50
pg/mL). The plates were incubated at 37 °C over night and stained by vaporizing
a few iodine crystals in the inverted plate lids. The blue clones stained by the
iodine had their amylase deficient phenotypes, which were correct constructs.
The insertions of fusion genes into the chromosome amyE locus had led to the
disruption of the amyE gene and dysfunctional AmyE protein, which could not
disintegrate the starch.
Note that AmyE protein (a-amylase) can break down starch into small
structural units (e.g., maltotriose and maltose). Thereby, the presence of AmyE
protein would have failed the starch-iodine test (colorless). The clones showed
blue in the starch-iodine test, confirming the successful insertion of each BmrAEGFP fusion gene into the chromosomal amyE locus. Furthermore, these two
new strains fully grew in the medium, and reached confluent at the same time as
WT-BmrA and ABmrA strains. The results suggest non-clonal effects.
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The expression of fusion genes in single live cells was characterized by
measuring fluorescence of EGFP. The cell suspension in the PBS buffer were
imaged in a micro-chamber using dark-field optical and epi-fiuorescence
microscope (Nikon, E-400), equipped with a CCD camera (Micromax, Roper
Scientific). We have fully described the design and construction of the micro
chamber and dark-field optical and epi-fluorescence microscope for imaging of
single cells in our previous studies [37, 38, 73, 75, 89, 90], In this study, the
fluorescence filter cube (Chroma Tech) containing a band-pass excitation filter
(455 ± 30 nm), band-pass emission filter (525±30 nm) and a dichroic mirror (500
nm), was used for fluorescence imaging of expression of BmrA-EGFP.

Fluorescence spectroscopic study of accumulation kinetics of dyes in live
cells
Fluorescence intensity of Hoechst 33342 (2 pM) incubated with the cells
(OD6oo nm = 0.1) in the PBS buffer, in the presence or absence of glucose (25
mM), and in the presence or absence of a pump inhibitor (25 pM orthovanadate)
were acquired over time with 3 s time interval at room temperature using a
fluorescence spectrometer (Perkin-Elmer, LS50B). The excitation and emission
wavelengths were selected at 350 and 450 nm, respectively.

Structural modeling of fusion BmrA-EGFP transporters
The BmrA model was assembled using SWISS-MODEL, based upon
existing homologous structural models of the ‘closed’ multidrug ABC transporter
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Sav1866 and LmrA with up to 33.7% sequence identity (PDB-codes: 2onj, 2hyd,
1mv5) [84, 85]. The N- (24 amino acids) and C- (15 amino acids) terminal
regions of this model were truncated, based on residues 269-829 of the template
model Sav1866 (2hyd). The total energy of the complete model was reported as 16525.7 kJ/mol.
The EGFP model was assembled separately using SWISS-MODEL,
based on 3D structure of the GFP (PDB-code: 3ogo) with a sequence identity of
98.7%. The structure was truncated by 7 amino acids at the N-terminal and 3
amino acids at the C-terminal.
To predict the secondary structures of the truncated regions connecting
the EGFP domain to BmrA, the complete protein sequences of the fusion
proteins were analyzed using the PSIPRED server [86]. The results (Fig. 11A-B)
predicted the linker regions to be unstructured and thus conformationally flexible.
The flexible linker regions were built manually and docked to the homology
model termini using program Coot [91]. The EGFP domains were positioned as
such that they were situated in the cytoplasmic space with no clashes to the ABC
transporter. The final models (Fig. 11C-D) were visualized using PyMOL [92].
Note: All experiments in this dissertation were conducted in compliance
with the university safety guidelines. The IBC approval number for recombinant
DNA research in chapter II & IV is 12-008.

CHAPTER III
PROBING OF MULTIDRUG ABC MEMBRANE TRANSPORTERS OF
SINGLE LIVING CELLS USING SINGLE PLASMONIC NANOPARTICLE
OPTICAL PROBES

INTRODUCTION
ATP-binding cassette (ABC) membrane transporters (efflux pumps) have
been found in all living organisms, including bacteria and humans [52, 53]. For
example, 78 ABC transporters have been reported in B. subtilis, and 48 ABC
transporters have been identified in humans [52, 53, 55, 56]. Some of these
transporters are involved in transport of a wide variety of structurally and
functionally unrelated substrates (e.g., sugars, lipids, amino-acids, proteins, or
xenobiotics), including extrusion of antibiotics or chemotherapeutic agents out of
cells (e.g., bacteria or tumor cells). For example, P-glycoprotein accounts for
multidrug resistance (MDR) in cancer cells, leading to ineffective treatments.
Dysfunction of some of these ABC transporters causes severe diseases [9-11].
Despite extensive studies, such important and fascinating multi-substrate
extrusion machinery and translocation mechanisms remain

not yet fully

understood [9, 52, 53].
Interestingly, all ABC transporters in any living organism share a common
organization, possessing four core domains: two transmembrane domains (TMD)
and two nucleotide-binding domains (NBD) [46, 59, 61, 93], The TMDs display
quite variable sequence and topology, defining the substrate binding-sites and
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forming the transport passage-way for substrates to cross the membranes, while
the NBDs have conserved sequences, empowering the transporters by binding
and hydrolyzing ATP [46, 57, 61, 62], The similar structures and organization of
ABC transporters suggest possible similar transport mechanisms.
B. subtilis (a Gram-positive bacterium) is a well-studied bacterium with a
full-sequenced genome, and it is amenable to genetic manipulation [80],
Therefore, B. subtilis has been widely used as a model organism for probing the
function of prokaryotes and for better understanding of bacterial pathogenic
functions

(e.g.,

sporulation)

and

efflux function

of multidrug

membrane

transporters, even though B. subtilis itself is not considered as a human
pathogen [94, 95].
Currently,

radioactively

labeled

substrates

(14C and

3H)

and

the

fluorescence dyes (e.g., rhodamine 123, Fluo-3, Hoechst dyes) are common
probes for investigating efflux kinetics of multidrug transporters in bacterial and
mammal cells [68, 69, 74, 76]. Fluorescence dyes, such as Hoechst dyes and
ethidium bromide (EtBr), are quinolones, common substrates for multidrug
membrane

transporters

in

bacteria.

The

fluorescence

dyes

emit weak

fluorescence in aqueous solution (outside cells) and become strongly fluorescent
in non-polar and hydrophobic environments, especially as the dye molecules
enter cells and intercalate with DNA [77]. Therefore, the time-dependent (timecourse) fluorescence intensity of fluorescence dyes has been widely used to
characterize efflux function of multidrug membrane transporters in bacterial and
mammal cells [68, 69, 74, 76],

Although these conventional

methods effectively provide ensemble

accumulation kinetics of bulk cells, they are unable to determine transformation
of pore sizes of ABC membrane transporters in response to various sizes of
substrates in single living cells. Therefore, it is impossible to use them for probing
size-dependent efflux kinetics of multidrug (multi-substrate) ABC membrane
transporters

for

better

understanding

of

their

functions

and

molecular

mechanisms. These limitations demand the development of new methods for
probing the size-transformation of individual membrane transporters in single
living cells in real time, in order to better understand molecular mechanisms of
multidrug membrane transporters. Individual membrane transporters are likely to
have unsynchronized membrane transport kinetics, underscoring the importance
of probing the transport kinetics of single membrane transporters in single living
cells in real time.
Currently, the sizes of membrane transporters are characterized at atomic
resolution using X-ray crystallography or cryo-TEM [61, 93, 96]. However, neither
methods can measure real-time transport dynamics of substrates and selfassembly of pump proteins in living cells. Therefore, the mechanisms and
functions of membrane transporters remain elusive, even through structures of
some membrane transporters at atomic resolution are now available [61, 93, 96].
Noble metal (e.g., Ag) nanoparticles (NPs) exhibit size-dependent optical
properties, enabling us to image and determine the sizes of single NPs at
nanometer (nm) scale in real time using dark-field optical microscopy and
spectroscopy (DFOMS) [42-44, 73, 75, 90]. Notably, the size-dependent

localized surface plasmon resonance (LSPR) spectra (colors) of single NPs
enable us to image the sizes of NPs in solution, single living cells and embryos at
nm resolution in real time [39, 43, 44, 75, 89, 90, 97, 98]. These unique features
allow us to use the color (LSPR spectra) index of the multicolor NPs as a
nanometer-size index to directly measure sizes of single NPs as they are
transported in and out of single living cells, and thereby to determine the sizes of
membrane pores at the nm resolution in real-time [75, 89, 90]. Unlike fluorescent
probes and semiconductor quantum dots (QDs), these noble metal NPs resist
photodecomposition and blinking and show superior photostability [43, 44, 97],
enabling them to serve as optical sized probes for tracking the transformation of
pore sizes of membrane transporters and the size-dependent transport kinetics
of efflux pumps for any desired period of time.
We have previously used the intrinsic optical properties of the noble metal
NPs (e.g., Ag) for probing of sizes and transport dynamics of a single membrane
transporter (MexA,B-OprM) in single living cells (P. aeruginosa, Gram-negative
bacterium), and the transformation of pore sizes of their cellular membranes
induced by antibiotics (e.g., aztreonam, chloramphenicol) at sub-100 nm spatial
resolution and millisecond temporal resolution [75, 89, 90],
In this study, we synthesized and characterized stable and purified
spherical Ag NPs with an average diameter of 11.8 ± 2.6 nm (8.4-31.5 nm). We
used their sized-dependent LSPR spectra to determine the sizes of single NPs at
nm resolution in real time, when they were in and out of single living cells, which
enabled us to probe size-dependent efflux kinetics of BmrA (one of ABC

43
membrane transporters) of single living bacterial cells (B. subtilis, Gram-positive
bacterium). We also used the Ag NP probes to characterize BmrA fused with
EGFP via its C- or N- terminus (Ct-BrmA-EGFP, or Nt-BmrA-EGFP) and to
compare them with BmrA, aiming to determine whether the fused BmrA-EGFP
maintains the efflux function of BmrA. We need to first determine whether BmrAEGFP maintains the original efflux functions of BmrA, before we can use fused
EGFP to visualize the BmrA locations and to characterize BmrA topologies, as
those reported for other ABC transporters [65-67, 81].

RESULTS AND DISCUSSION
Synthesis and characterization of single Ag NP optical probes
We have synthesized spherical shaped Ag NPs and purified them by
washing the NPs with nanopure deionized (Dl) water using centrifugation. This
approach enables us to remove any residual chemicals from the synthesis and to
produce highly purified NPs. We found that the purified Ag NPs were stable in Dl
water for months, as we reported previously [44] . In order to maintain the
viability of bacterial cells (B. subtilis), the cells must be suspended and incubated
in the cell culture media or PBS buffer (0.5 mM phosphate buffered saline, 1.5
mM NaCI). Notably, the studies of accumulation and efflux kinetics of multidrug
membrane transporters (efflux pumps) in bacterial cells (Gram-negative or Grampositive bacteria) using fluorescence molecules have been carried out in the
buffer solution (PBS buffer), but not in the cell culture medium [54, 68, 71-73, 99].

Given concentrations and stages of the cells (e.g.,

O D 6oonm

= 0.1) must be

incubated with given concentrations of fluorescence molecules (substrates), in
order to determine the dependence of accumulation and efflux kinetics of
membrane transporters on substrate concentrations and on the expression level
of membrane transporters in given cells. Note that the cells grow and divide in
the medium, leading to the change of cell concentrations and thereby impossible
comparison of the results among the experiments. Therefore, the cells are
typically harvested from cell culture media, well rinsed and dispersed in the PBS
buffer with given concentrations (e.g.,

O D 6 oo nm

= 0.1) for probing of transport

kinetics of membrane transporters in living cells [54, 68, 71-73, 99].
It is crucial to ensure that single Ag NPs are stable (non-aggregated) in
the PBS buffer over time, in order to utilize the size-dependent LSPR spectra
(colors) of single NPs to determine their sizes, to probe the pore sizes of
membrane transporters and to study size-dependent and

concentration-

dependent efflux kinetics of single membrane transporters of single living cells in
the buffer.
We characterized the sizes, shapes and LSPR spectra of purified Ag NPs
in the buffer for 24 h at single-NP resolution using high-resolution transmission
electron

microscopy

(HRTEM)

and

dark-field

optical

microscopy

and

spectroscopy (DFOMS), respectively. This approach enabled us to study the
stability (non-aggregation) of purified Ag NPs in the buffer for 24 h at single-NP
resolution. The results in Fig. 12A and B show single spherical NPs with an
average diameter of 12.1 ± 4.8 nm, ranging from 8.4 to 31.5 nm. The
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representative optical images of single NPs in Fig. 12C show that the majority of
NPs are plasmonic blue NPs with some being green and few red NPs.
Histograms of color (size) distribution of single NPs (Fig. 12D) from 20 images
similar to that in Fig. 12C, show 74% blue, 22% green and 4% red NPs (Fig.
12D-a), and 71% blue, 24% green and 5% red NPs (Fig 12D-b), before and after
the NPs were dispersed in the buffer for 24 h, respectively.
We correlated the size distribution of single NPs measured by HRTEM
(Fig. 12B) with the color (peak-wavelength of LSPR spectra) distribution of single
NPs characterized using DFOMS (Fig. 12D), and found that blue, green and red
NPs were correlated with NPs with diameters of 5-14 nm, 14-20 nm, and 20-32
nm, respectively [39, 75]. Therefore, we used the LSPR spectra (colors) of single
NPs to determine their sizes in real-time, and used them as sized-probes to
characterize the transformation of pore sizes of membrane transporters in single
living cells and to study the size-dependent transport kinetics of multidrug
membrane transporters (BmrA) of single living cells.
We also characterized the sizes, optical properties and stability (non
aggregation) of bulk Ag NPs in the buffer for 24 h using UV-visible absorption
spectroscopy and dynamic light scattering (DLS). The UV-visible absorption
spectra of purified Ag NPs before and after their incubation in the buffer for 24 h
show an unchanged peak absorbance of 1.047 at 392 nm (Fig. 12E). The size
distributions of the Ag NPs before and after their incubation in the buffer for 24 h
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Fig. 12 Characterization of sizes, shapes and plasmonic optical properties
of single Ag NPs, and their stability (non-aggregation) in PBS buffer.
NPs dispersed in the PBS buffer for (a) 0 min and (b) 24 h. (A) Representative
HRTEM image and (B) histogram of the size distribution of Ag NPs. (C)
Representative dark-field optical image o f single NPs and (D) histograms of color
distribution of single NPs. (E) UV-visible absorption spectra of 1.4 nM Ag NPs
show peak absorbance of (a) 1.047 at 392 nm and (b) 1.043 at 392 nm. (F)
Histograms of size distribution of single NPs in solution measured using DLS
show the average diameters of NPs at (a) 11.8 ± 2.6 nm and (b) 11.8 ± 2.8 nm.
The scale bars are 10 nm in (A) and 10 pm in (C)

characterized using DLS show the same distribution range with the average
diameters of NPs at 11.8 ± 2.6 nm and 11.8 ± 2.8 nm (Fig. 12F), respectively.
The results indicate that the sizes of Ag NPs in the buffer remain unchanged for
24 h. Interestingly, unlike our previous observations [44], the diameters of NPs
measured in solution by DLS were slightly smaller than those measured under
vacuum using HRTEM, which may be attributed to the negligible portion of larger
NPs (18-30 nm in diameter) for ensemble measurements of DLS. In this study,
the NPs in the buffer solution were used to characterize the efflux function of the
BmrA transporter in single living bacterial cells (B. subtilis). Therefore, the
average diameter of NPs is the one (11.8 ± 2.6 nm) measured in solution using
DLS. Taken together, the results in Fig. 12 show that purified Ag NPs are stable
in the buffer solution for 24 h.

Real-time probing of size-dependent efflux kinetics of BmrA using single
Ag NPs
We used the size-dependent LSPR spectra (plasmonic properties) of
single Ag NPs to probe the size-dependent efflux function of BmrA by incubating
the Ag NPs with the living cells

( O D 6o o n m

= 0.1) and tracking single NPs in and

out of single living cells in real time.
The representative optical images of the cells with single intracellular and
extracellular NPs in Fig. 13A and B show cross-sections of single rod-like
bacterial cells. The size of single bacterial cells is about 2 pm in length and 0.5
pm in width while the thickness of its cellular membrane is about 9 nm. Notably,
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the top and bottom membranes of single living cells are invisible under dark-field
illumination, which demonstrates that the focal plane (depth of field at 190 nm) of
dark-field microscope indeed allows us to image the thin-layer sections of single
living bacterial cells and to visualize single NPs on the thin-layer section of single
cells.
The dark-field microscope illumination needs to pass through the cellulaV
membrane in order to irradiate intracellular NPs, and light scattering of
intracellular NPs requires passage through the membrane in order to be imaged
by the detector. The cellular membrane absorbs photons, leading to lower
scattering intensity of intracellular NPs (dimmer). In contrast, the scattering
intensity of the extracellular NPs on the membrane contains the scattering
intensity of NPs and cellular membrane, leading to radiating imaging and higher
scattering intensity. These features allow us to distinguish between the
intracellular and extracellular NPs. The intracellular NPs are dimmer and more
blurry than NPs in solution, as shown in Fig. 13A-a and B-a. In contrast, the
extracellular NPs are radiating and much brighter than NPs in solution, as shown
in Fig. 13A-b and B-b. Notably, we have validated these imaging approaches for
determining intracellular and extracellular NPs by imaging ultra-thin sections of
cells using TEM [75].
The representative LSPR spectra of single NPs in Fig. 13C show their
peak wavelength (Amax) at 481 (blue), 535 (green) and 649 nm (red) NPs. Using
the LSPR spectra (colors) of single Ag NPs, we identified the Ag NPs over any
other possible cellular debris and vesicles, which do not have plasmonic
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properties and thereby appear white under dark-field illumination. Furthermore,
size-dependent plasmonic spectra enable us to determine the sizes of single
NPs in real-time using DFOMS via the calibration curves of the peak wavelength
(A m ax)

of LSPR spectra of single NPs versus their sizes, as we reported

previously [39, 44, 75, 89, 90]. The sizes of single blue, green and red NPs in
Fig. 13C are 13.3, 21.8, and 31.5 nm, respectively.
We incubated WT BmrA cells (ODeoonm = 0.1) with 1.4 nM Ag NPs and
continuously imaged single NPs in and out o f single living cells in real time.
Snap shots from real-time videos in Fig. 14A and B show representative single
blue and green NPs in and out of single living cells, respectively. The plots of
single NPs in and out of singe living cells over time (Fig. 14C) show that the blue
NP stays inside the cell for 66 min, while the green NP stays inside the cell for 14
min. The LSPR spectra of the blue and green NPs, similar to the one in Fig. 13C,
show the peak wavelength

(A m ax)

at 479 nm and 540 nm, respectively.

We

determined the sizes of single blue and green NPs as 13.0 and 22.6 nm,
respectively, using the correlation of sizes of single NPs determined by HRTEM
with the peak wavelength of LSPR spectra (colors) of single NPs measured using
DFOMS, as we reported previously [39, 75]. The results show that the smaller
NPs stay inside the cell longer than larger NPs, suggesting size-dependent efflux
kinetics of BmrA and indicating that smaller NPs are more biocompatible with the
cells and they may be more suitable carriers for drug delivery.
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Fig. 13 Imaging of single intracellular and extracellular Ag NPs for single
living bacterial cells using DFOMS.
(A) The representative optical image of the cells (BmrA, OD6oo

nm

= 0.1)

incubated with 1.4 nM Ag NPs shows: (a) intracellular and (b) extracellular NPs,
in dotted rectangles. (B) Zoom-in images of single cells illustrate (a) intracellular
and (b) extracellular NPs. (C) LSPR spectra of single Ag NPs show peak
wavelengths of representative blue, green, and red NPs at 481, 535, and 649 nm,
respectively. The scale bars in (A) and (B) are 10 and 2 pm, respectively
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Taken together, plasmonic Ag NPs offer the feasibility for probing of sizedependent efflux kinetics of membrane transporters in single living cells in real
time. Unlike fluorescence probes (e.g., Hoechst dyes), single Ag NPs possess
size-dependent

LSPR

spectra

and

they

are

photostable

(non

photodecomposition and non-blinking) [43, 44, 97], These superior properties
enable us to determine the sizes of single NPs in and out of single living cells in
real-time, and use them to mimic various sizes of antibiotics (drugs) for probing
efflux functions of multidrug membrane transporters.

Probing of dependence of accumulation rates of NPs on expression level of
BmrA
To determine whether BmrA and BrmA-EGFP are responsible for
extrusion of NPs out of living cells, we studied the dependence of accumulation
kinetics of intracellular NPs upon the expression level of BmrA and BmrA-EGFP
in bulk living cells at single living cell resolution. The results in Fig. 15A show that
ABmrA (strain of deleted BmrA) cells accumulate the highest amount of the
intracellular NPs over time and have the highest accumulation rate (slope of the
plot) of intracellular NPs, while the Nt-BmrA-EGFP cells (over expression level of
BmrA with its N-terminal fusion with EGFP) accumulate the lowest amount of
intracellular NPs and show the lowest accumulation rate.
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Fig. 14 Real-time probing of BmrA membrane transporter of single living
cells using single Ag NPs by DFOMS.
Snapshots of sequential images of (A) a single blue NP (13.0 nm in diameter) in
and out of single living BmrA cells at (a) 18.0, (b) 32.0, (c) 47.0, (d) 60.0, (e)
74.0, and (f) 83.0 min; and (B) a single green NP (22.6 nm in diameter) in and
out of single live cells at (a) 30.0, (b) 33.0, (c) 35.0, (d) 38.0, (e) 41.0, and (f) 44.0
min. (C) Plots of imaging of in and out of single NPs in (A and B) versus time
show the duration of single blue and green NPs staying inside the cells: (a) 66.0
and (b) 14.0 min, respectively
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Fig. 15 Study of the dependence of accumulation and efflux kinetics of
single Ag NPs and fluorescent dye (Hoechst 33342) molecules on the
expression level of BmrA.
(A) Plots of number of intracellular Ag NPs versus time and (B) plot of
fluorescence intensity versus time for: (a) ABmrA, (b) Ct-BmrA-EGFP, (c) WTBmrA, and (d) Nt-BmrA-EGFP cells, show that accumulation kinetics of
intracellular NPs and fluorescence dye molecules in single living cells depend on
cellular expression level of BmrA. In (A), the points with error bars represent the
averages of experimental measurements with their standard deviations; the lines
are added to guide the trend. At each point (every 20 min), 900 cells were
analyzed
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Interestingly, the accumulation rate and amount of intracellular NPs in NtBmrA-EGFP cells are slightly lower than the WT (normal expression level of
BmrA), while the accumulation rate in WT cells is slightly lower than Ct-BmrAEGFP cells (over expression level of BmrA with its C-terminal fusion with EGFP).
The results suggest that WT (BmrA), Nt-BmrA-EGFP and Ct-BmrA-EGFP cells
extrude the intracellular NPs, leading to less accumulation of intracellular NPs
than ABmrA cells. The results indicate that Nt-BmrA-EGFP and Ct-BmrA-EGFP
maintain the efflux function of BmrA, and N-terminal fusion generates less steric
effects on the efflux function of BmrA than C-terminal fusion.
The sizes of NPs are about ten times larger than conventional antibiotics.
To determine whether the NPs are suitable substrates to mimic various sizes of
antibiotics for probing the efflux functions of BmrA, we used a fluorescence probe
(Hoechst 33342) to study the dependence of accumulation kinetics on the
cellular expression level of BmrA for probing the efflux function of BmrA and
BmrA-EGFP membrane transporters [54, 76]. The Hoechst dye is a well-known
substrate of BmrA (ABC) membrane transporter and has been widely used for
probing the accumulation and efflux function of BmrA. The Hoechst dye emits
weak fluorescence in aqueous solution (outside the cells), and its fluorescence
intensity increases substantially (up to 10-fold) as the dye molecules enter the
cells and intercalate with DNA [77]. Therefore, one can use the fluorescence
intensity of the Hoechst dye to monitor intracellular accumulation of dye
molecules [54, 76]. By probing the dependence of the accumulated amount of
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the intracellular dye molecules on the expression level of BmrA membrane
transporters, we determined the efflux kinetics of BmrA and BmrA-EGFP.
The results in Fig. 15B show that ABmrA cells accumulate the largest
amount of intracellular dye molecules with the highest rate of accumulation
(slope of the curve), whereas Nt-BmrA-EGFP cells accumulate the lowest
amount of intracellular dye molecules with the lowest rate of accumulation.
Notably, Nt-BmrA-EGFP cells, which have slightly lower accumulation rate and
lower amount of the intracellular dye molecules than the WT cells, which have
slightly lower ones than Ct-BmrA-EGFP cells. The results suggest that WT
(BmrA), Nt-BmrA-EGFP and Ct-BmrA-EGFP extrude the dye molecules and
thereby they accumulate less amount of the intracellular dye molecules than
ABmrA cells, demonstrating that N-terminal or C-terminal BmrA fusion with
EGFP maintains the efflux function of BmrA, and N-terminal fusion has less
effect on the efflux function of BmrA than C-terminal fusion. Therefore, Nt-BmrAEGFP and Ct-BmrA-EGFP cells become two new strains of BmrA available for
further characterization of locations, structures and functions of BmrA. The
results in Fig. 15B are similar to those observed using single NP optical probes
(Fig. 15A), suggesting that single NP optical probes are well suited substrates for
probing the efflux function of multidrug membrane transporters.
Unlike fluorescence probes, Ag NPs offer size information about the
membrane permeability and substrates of the membrane transporters. The NPs,
with sizes ranging from 8.4-31.5 nm, can enter the cells and be extruded out of
the cells by BmrA and BmrA-EGFP transporters. Specifically, endocytosis,
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pinocytosis and exocytosis, which are widely reported in eukaryotes, do not exist
in prokaryotes (bacterial cells). Therefore, these processes are not responsible
for the transport of NPs in and out of the bacterial cells (S. subtillis).

Study of effect of pump inhibitor on accumulation rates of NPs in single
living cells
To determine whether BmrA and BmrA-EGFP membrane transporters are
specifically responsible for the efflux of NPs, we studied the accumulation
kinetics of the NPs in BmrA (WT), ABmrA, Nt-BmrA-EGFP and Ct-BmrA-EGFP
living cells in the presence of a pump (ATPase) inhibitor, orthovanadate [82, 83].
The results in Fig. 16A show the higher accumulation rate of the NPs in the cells
(WT-BmrA) in the presence of orthovanadate (Fig. 16A-a) than in its absence
(Fig. 16A-b). In contrast, no significant change of accumulation of NPs in ABmrA
cells was observed in the presence of the inhibitor (Fig. 16B).
Similar to WT cells, higher accumulation of NPs in Ct-BmrA-EGFP and NtBmrA-EGFP cells was observed in the presence of the inhibitor than its absence
(Fig. 16C and D, respectively). These results show that the inhibitor affects the
efflux of NPs by Ct-BmrA-EGFP, Nt-BmrA-EGFP and WT-BmrA transporters,
suggesting that BmrA and BmrA-EGFP membrane transporters are indeed
responsible for the efflux of NPs out of the cells. These results demonstrate that
the NPs are the substrates of BmrA, and they are suitable optical probes to study
efflux function of BmrA membrane transporters in single living cells.
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Study of concentration-dependent accumulation rates of NPs in single
living ceils
We also investigated the dependence of accumulation rates of NPs on
their concentrations (doses), in order to determine molecular mechanisms of
entry of NPs into single living cells, and to compare them with those observed for
antibiotics. We used two concentrations of NPs (0.7 and 1.4 nM) and studied
their accumulation rates in BmrA (WT), ABmrA, Ct-BmrA-EGFP, and Nt-BmrAEGFP cells. The results in Fig. 17 show the dependence of the number of
intracellular NPs on NP concentrations for all strains of cells and the number of
intracellular NPs increases as the concentration of NPs increases, suggesting
that passive diffusion may play a role in transport of extracellular NPs into the
cells, similar to passive diffusion of antibiotics into the cells.
The lowest number of intracellular NPs and lowest accumulation rates are
observed in Nt-BmrA-EGFP (Fig. 17D), while the highest number of intracellular
NPs and highest accumulation rates are found in ABmrA (Fig. 17B). Notably, the
number of intracellular NPs at the equilibrium time, and accumulation rates in
BmrA (WT) and Ct-BmrA-EGFP cells are similar to those observed in Nt-BmrAEGFP. The results suggest that ABmrA cells are unable to extrude the NPs out
of the cells, because of the absence of BmrA transporter, which leads to the
highest accumulation of intracellular NPs. In contrast, the over-expression of NtBmrA-EGFP transporter effectively extrudes the NPs out of the cells, leading to
the lowest accumulation of intracellular NPs.

BmrA (WT) and Ct- BmrA-EGFP

transporters extrude NPs out of the cells (Fig. 17A and C), leading to the lower
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Fig. 16 Probing of inhibitory effects of an inhibitor on accumulation and
efflux kinetics of single Ag NPs for single living cells.
Plots of intracellular Ag NPs versus time: (A) BmrA, (B) ABmrA, (C) Ct-BmrAEGFP, and (D) Nt-BmrA-EGFP, (a) in the absence (empty triangles) and (b)
presence (filled triangles) of the inhibitor (25 pM, orthovanadate). The points with
error bars represent the averages of three experimental measurements with their
standard deviations; the lines are added to guide the trend. At each point (every
20 min), 900 cells were analyzed
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Fig. 17 Study of concentration dependent accumulation and efflux kinetics
of single Ag NPs for single living cells.
Plots of intracellular Ag NPs versus time: (A) BmrA, (B) ABmrA, (C) Ct-BmrAEGFP, and (D) Nt-BmrA-EGFP cells, incubated with (a) 1.4 (filled triangles) and
(b) 0.7 nM (empty triangles) Ag NPs. The points with error bars represent the
averages of three experimental measurements with their standard deviations; the
lines are added to guide the trend. At each point (every 20 min), 900 cells were
analyzed
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accumulation of intracellular NPs than ABmrA cells. Therefore, the accumulation
rates of intracellular NPs in BmrA (WT) and Ct-BmrA-EGFP cells are similar to
those observed in Nt-BmrA-EGFP. As observed in Figs. 15A and 16, the results
in Fig. 17 also show the dependence of accumulation rates of intracellular NPs
on the expression level of BmrA.
We summarize quantitative accumulation rates and equilibrium times of
accumulation of intracellular NPs in single living cells (Figs. 16 and 17) in Table
2, which

shows their dependence

on

the

expression

level

of

BmrA,

concentrations of NPs, and presence of the inhibitor.

Characterization of viability of single cells
Studies have found that Ag NPs show dose-dependent inhibitory effects
on bacterial and tumor cells [39, 100]. Therefore, it is crucial for us to
characterize the viability of cells that had been incubated with Ag NPs for hours,
ensuring that Ag NPs did not affect the function and viability of the cells, and we
indeed studied the membrane transporters (BmrA, BmrA-EGFP) of single living
cells.
The viability of cells (WT, BmrA-EGFP, ABmrA) incubated with NPs
throughout the duration of the experiments was characterized using live/dead
bacL/ght viability and counting assay. The assay determines the viability of cells
by detecting both live and dead cells using SYT09 nucleic acid stain and
propidium iodide, respectively. Observation of the green fluorescence (Amax = 520
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nm) of SYT09 in bacterial cells shows viable cells. In contrast, the display of red
fluorescence (Amax = 610 nm) of propidium iodide in bacterial cells indicates the

Table 2 Summary of accumulation rates and equilibrium times of single
NPs in single living cells

C Ag NPs
(nM)

Inhibitor3

Accumulation Rate

Equilibrium Time

(NPs/min)

(min)

(MM)
WT

ABmrA

Ctb

Ntc

WT

ABmrA

Ctb Ntc

0.7

0

1.1

1.6

1.0

1.1

40

60

40

40

1.4

0

1.5

1.8

1.3

1.2

40

60

40

40

1.4

25

1.7

1.8

1.9

2.1

80

120

80

80

a Orthovanadate
b Ct-BmrA-EGFP: cells with the over-expression of C-terminus BmrA fused with
EGFP
0 Nt-BmrA-EGFP: cells with the over-expression of N-terminus BmrA fused with
EGFP
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B

BmrA

ABmrA

Ct-BmrA

Nl-BmrA

Fig. 18 Characterization of the viability of single bacterial cells using
live/dead bacLight viability and counting assay.
(A) Dark field optical image and (B) fluorescence image of single bacterial cells
(WT BmrA), incubated with 1.4 nM Ag NPs over the duration of each experiment
for 4 h, show that the cells with intracellular NPs (dotted rectangles) or without
NPs emit the green fluorescence

( A ma x =

520 nm) o f SYT09, indicating viable

cells, (c) Plots of percentage of viable cells at (a) 0 and (b) 4 h, for BmrA, ABmrA,
Ct-BmrA-EGFP, and Nt-BmrA-EGFP cells, show that 99-100% of the cells are
alive. A minimum of 900 cells for each strain were assayed at each given time.
The scale bars in (A) and (B) are 10 pm
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dead cells. Representative optical images of the cells (WT-BmrA) incubated in
the PBS buffer with 1.4 nM Ag NPs for 4 h (Fig. 18A), show the cells with and
without NPs. Their fluorescence images in Fig. 18B illustrate the green
fluorescence cells, showing that the cells with and without NPs are alive. Similar
phenomena are observed for Ct-BmrA-EGFP, Nt-BmrA-EGFP, and ABmrA cells.
By counting the number of live and dead cells, we determined the
percentage of the viable cells by dividing the number of live cells with the total
number of the cells. Note that, for each measurement, we assayed at least 900
cells for each strain. The plots of the percentage of viable cells at the beginning
and end of experiments in Fig. 18C show that more than 99% of the cells for
each strain (WT, Ct-BmrA-EGFP, Nt-BmrA-EGFP, and ABmrA) were alive and
viability remained

constant throughout the duration of the experiments,

demonstrating that we indeed studied the membrane transporters of single living
cells. The results show that the NPs at these selected concentrations (1.4 nM)
are biocompatible to the cells, demonstrating that the NPs are well suited for
probing of membrane transporters of single living cells in real time.

SUMMARY
In summary, we have prepared purified and stable (non-aggregation) Ag
NPs (11.8 ± 2.6 nm). In the given doses (1.4 nM), they are biocompatible with
the cells. We utilized the size-dependent LSPR spectra of single NPs to
determine the sizes of single NPs in and out of single living cells (B. subtilis) at
nanometer resolution in real time using DFOMS, and to probe size-dependent

efflux kinetics of single BmrA membrane transporters (Ct-BmrA-EGFP, Nt-BmrAEGFP) in single living cells in real-time. The results show that Nt-BmrA-EGFP
and Ct-BmrA-EGFP transporters maintain the efflux function of BmrA, offering
two new strains for the future study of BmrA. We found that the smaller NPs
resided longer inside the cells than larger NPs, suggesting the size-dependent
efflux kinetics of BmrA and indicating that smaller NPs are more biocompatible
with the cells. Furthermore, accumulation and efflux rates of NPs for single living
cells are dependent on the expression level of BmrA, concentration of NPs, and
a pump inhibitor (orthovanadate), similar to those observed using a well-known
substrate (Hoechst dye) of BmrA transporter, suggesting that NPs are substrates
of BmrA transporters and they enter the cells via passive diffusion. Taken
together, this study demonstrates that single plasmonic Ag NP optical probes are
superior to fluorescence probes for study of efflux kinetics of multidrug
membrane transporters in single living cells. Single Ag NPs exhibit sizedependent

LSPR

spectra

and

photostability

(non-blinking

and

non

photodecomposition), offering the feasibility of using them to mimic various sizes
of antibiotics (drugs) for probing the size-dependent efflux kinetics of membrane
transporters of single living cells at nm resolution in real-time.

METHODS
Reagents and cell lines
Live/dead bacL/ght viability and counting assay and Hoechst 33342 were
purchased from Invitrogen; all other reagents were purchased from Sigma-
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Aldrich, and used as received. For cell lines of Bacillus subtilis, W T (BmrA) were
purchased

from

Bacillus

Genome

Stock

Center

(BGSC),

while

ABmrA

(previously named AYvcC, a mutant strain that is void of the BmrA) were
provided by J. M. Jault [54], The cell lines of Ct-BmrA-EGFP (54A, a mutant with
over expression level of BmrA with its C-terminal fusion with EGFP) and NtBmrA-EGFP (29A, a mutant with over expression level of BmrA with its Nterminal fusion with EGFP) were constructed in our laboratory. The design and
characterization of Nt-BmrA-EGFP and Ct-BmrA-EGFP will be fully described
and reported in elsewhere.

Synthesis and characterization of Ag NP optical probes
Silver NPs were synthesized and washed as we described previously [44,
97]. The purified Ag NPs were dispersed in the PBS buffer (0.5 mM phosphate
buffer, 1.5 mM NaCI, pH = 7.0). We characterized the sizes, concentrations and
number of single NPs in the buffer over time to determine the stability (non
aggregation) of NPs in the buffer. The sizes of single NPs were determined using
high-resolution transmission electron microscopy (HRTEM) (FEI Tecnai G2 F30
FEG) and dynamic light scattering (DLS) (Nicomp 380ZLS particle sizing
system). The concentrations of NPs were measured and calculated, as described
previously [97, 101]. Plasmonic absorption and scattering properties of bulk NPs
were characterized using UV-visible spectrometer (Hitachi).
The plasmonic images and LSPR spectra of single NPs were acquired
using dark-field optical microscopy and spectroscopy (DFOMS) equipped with
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CCD camera (Micromax, Roper Scientific) and Multiple-spectra imaging system
(Nuance, CRI) [39, 43], The design and construction of DFOMS have been fully
described in our previous studies [37-39, 42, 43, 97, 98,]. The dark-field optical
microscope was equipped with a dark-field condenser (Oil 1.43-1.20, Nikon) and
a 100x objective (Nikon Plan fluor 100x oil, iris, SL. N.A. 0.5-1.3, W.D. 0.20 mm)
with the depth of field (focus) of 190 nm.

Cell culture and preparation
We pre-cultured the cells in an Erlenmeyer flask (250 mL) containing 20
mL of L-broth (LB) medium (1% tryptone peptone, 0.5% yeast extract, and 0.5%
NaCI, pH = 7.2) in a shaker (Lab-line Orbit Envivon-Shaker) (150 rpm, 37 °C) for
12 h. We then cultured the cells (WT and ABmrA) in the LB medium for another 8
h, and cultured the Ct-BmrA-EGFP and Nt-BmrA-EGFP cells in the medium
containing 1% xylose for another 8 h to ensure the full expression of the EGFP.
We harvested the cultured cells using centrifugation (Beckman Model J2-21
Centrifuge, JA-14 rotor, at 7500 rpm, 23 °C, 10 min), washed the cells with the
PBS buffer three times, and finally re-suspended the cells in the buffer. The final
concentration of the cells was adjusted to

O D 6oon m

= 0.1, and used for the entire

study.

Imaging of single NPs in single living cells and probing cellular viability
The cell suspension

( O D 6 oonm

= 0.1) containing 0.7 and 1.4 nM Ag NPs in

the absence and presence of orthovanadate (25 pM) were prepared. The timer
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was started to record the incubation time as the NPs were added into the cell
suspension.
We transferred the mixture (20 pL) into a freshly prepared microchamber
and continuously imaged and acquired LSPR spectra of single NPs in and out of
single living cells in real time for 3 h using DFOMS, which enabled us to
determine the sizes and positions of single NPs simultaneously. The construction
of microchamber for imaging of single bacterial cells over time was fully
described in our previous studies [37-39, 42, 43, 97, 98]. We could achieve the
temporal resolution up to 5 ms with sufficient high signal to noise ratios for
continuously imaging the transport of single NPs in and out of single living cells.
However, we found that the transport of single NPs in and out of single living
cells (Bacillus subtillis) was not a rapid process and a temporal resolution of
seconds to two minutes was sufficient to track their transport in real time. This
approach enabled us to avoid generating huge sizes (> 200 GB) of single data
files that would be unnecessary and hard to handle and analyze.
We also

sampled

the

mixture

(20

pL)

into a freshly

prepared

microchamber every 20 min and imaged the cells on ten representative locations
in the microchamber using DFOMS equipped with a CCD camera. This approach
enabled us to image massive amount of cells (3000 cells) for each sample to
gain sufficient statistics for probing the accumulation rates of bulk cells at single
cell resolution. We determined intracellular NPs and plotted them versus time to
measure the accumulation

rates of single NPs in the cells over time

(accumulation rate = slope of the plot).
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At the end of each experiment, the viability of the cells was characterized
using live/dead BacLight bacterial viability and counting assay [102]. We imaged
the cells using dark-field optical microscopy and epi-fluorescence microscopy,
and counted the green fluorescence cells (peak wavelength of fluorescence
spectra of SYT09, Amax = 520 nm) and red fluorescence cells (peak wavelength
of fluorescence spectra of propidium iodide, Amax = 6 1 0 nm) as live and dead
cells, respectively.

Fluorescence spectroscopy measurements
Time-dependent (time-course) fluorescence intensity of Hoechst 33342 (2
pM) incubated with the cells

( O D 6oo nm

= 0.1) was measured at a 3-s data

acquisition interval in real-time using a fluorescence spectrometer (Perkin-Elmer
LS50B). The excitation and emission wavelengths were 350 and 455 nm,
respectively.

Data analysis and statistics
For characterization of sizes, shapes, and LSPR spectra of single NPs
using HRTEM and DFOMS, a minimal of 100 Ag NPs were imaged for each
measurement. Each measurement was repeated three times. Thus, 300 NPs
were characterized for each solution.
We acquired ~30 cells in a single CCD image in real time simultaneously.
Therefore, we studied the transport of single NPs in and out of ~3Q of single
living cells for eacji measurement. We repeated the experiment three times and
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hence -9 0 cells were studied to determine the transport of single NPs in and out
of single living cells in real time.
We also acquired ten representative images of each cell suspension
incubated with 0.7 or 1.4 nM Ag NPs every 20 min for 3 h to study accumulation
rates of intracellular NPs in single living cells in the presence or absence of the
inhibitor (orthovanadate, 25 pM). Therefore, a minimal of -300 cells was imaged
every 20 min, and 2700 cells were studied over 3 h for each measurement. Each
experiment was repeated three times. Thus, 8100 cells were studied for each
sample, which allowed us to gain sufficient statistics for probing accumulation
rates and efflux kinetics of bulk cells at single cell resolution. We analyzed the
number of intracellular NPs in 900 cells (300 cells for each measurement) at
each 20 min, plotted them over time, and used the slope of the plots to determine
the accumulation rates of intracellular NPs in the cells in the presence and
absence of the pump inhibitor (orthovanadate, 25 pM). The equilibrium times of
accumulation of NPs in the cells were determined at the times when the
accumulation rates of intracellular NPs remained unchanged over time. The
amount of accumulated intracellular NPs for each strain refers to the amount of
intracellular NPs at the equilibrium time.
For the study of viability of single cells, a minimal of 300 cells incubated
with 1.4 nM Ag NPs for 12 h was assayed for each measurement. Each
measurement was repeated three times. Thus, 900 cells were assayed for each
sample.
Note: The following guidelines from the University of Oklahoma Health

Sciences Center were always followed whenever we are working with
nanoparticles involved in the research studies shown in chapter III & V
(http://www.ouhsc.edu/ibc/documents/NanoparticlesGuidelines-doc).
1. Wear lab coats at all times.
2. Wear gloves when handling nanoparticles and gloves must covere the
hand and the wrist.
3. Wear long arm sleeves where high levels o f exposure to nanoparticles
were anticipated.
4. Wear standard lab safety goggles.
5. Perform work in a chemical hood or biological safety hood.
a. Never conduct aerosol producing activities (such as sonication,
vortexing, or centrifuging) on an open lab bench.
b. Do

not

perform

activities

that

could

possibly

release

nanoparticles (such as emptying and opening of tubes) on an
open lab bench.
c. Hand solutions containing nanoparticles over disposable lab
bench covers.
6. Provide hand washing facilities in all labs. Wash hand after handling
nanoparticles.
7. Clean lab bench tops and other surfaces after each experiment using
a methanol solution appropriate for the particular type of nanoparticles
being used.
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CHAPTER IV
STUDY OF STRUCTURE AND EFFLUX FUNCTION OF EGFP FUSED
MEXA.B-OPRM MEMBRANE TRANSPORTER IN PSEUDOMONAS
AERUGINOSA

INTRODUCTION
MDR (Multidrug resistance) associated efflux pumps have been identified
in many organisms, ranging from bacteria to humans [2, 5, 8, 47], In bacteria, the
genes encoding for efflux pumps are usually located on the chromosome or
transmissible genetic elements like plasmids and it is well known that the efflux
pumps in bacteria confer lower susceptibility to antibiotics, however this does not
necessarily result in increased antibiotic resistance which may be contributed by
other causes than existence of efflux pumps [7, 103]. To date, five classes of
efflux pumps are found associated with multidrug resistance: the MF superfamily,
the SMR family, the multidrug and toxic-compound extrusion (MATE) family, the
ABC superfamily and the RND family. Those efflux pumps are different in the
number of assembled components, transmembrane domains, the energy
sources used by pumps as well as the types of substrates exported by pumps [2,
3, 5, 8, 46]. Among these MDR transporters, only the ABC efflux transporters are
primary transporters with the rest being secondary transporters utilizing sodium
or proton gradient as the source of energy, whereas the MF superfamily
dominates in gram-positive bacteria, the RND family only exists in gram-negative
bacteria [2, 5, 8, 103]. Besides from exporting multiple antibiotics out of cells,
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those efflux pumps are found to play new roles recently such that some efflux
pumps of the resistance-nodulation-cell division (RND) family have been
identified to have a role in the survival and colonization of the bacteria inside the
host. In addition, other efflux pumps are found to be capable of exporting natural
substances produced by the host [104-106].
Efflux pumps of RND family (e.g., MexA,B-OprM) which are expressed by
gram-negative bacteria and are found to be responsible for multidrug resistance
in clinical therapies

are tripartite

systems

including the following

three

components: a transporter protein (e.g., MexB), which is located on the inner
membrane of the bacterium; an outer-membrane protein (e.g., OprM), which is
located in the outer-membrane of the bacterium and a membrane fusion protein
(e.g., MexA) which is located in the periplasmic space [4, 107], Taking the MexA,
B-OprM efflux pump as an example, it is generally thought that the transporter
protein MexB captures its substrates either from within the lipid bilayer of inner
membrane or from cytoplasmic contents, then transports them to the extracellular
medium through OprM which forms a channel in the outer membrane [108]. The
cooperation between MexB and OprM is coordinated by the periplasmic
membrane fusion protein MexA [15, 109-112]. Efflux through RND-family pumps
is driven by the proton motive forces, an electrochemical gradient resulted from
the motion of hydrogen ions. Besides, the outer-membrane protein OprM of P.
aeruginosa is found to interact with several other RND family proteins [7, 111].
Despite extensive studies, the translocation

mechanisms of those

transporters remain elusive [109-111, 113, 114]. Many fundamental questions

regarding molecular mechanisms and interactions of multidrug efflux transporters
remain unanswered. For instance, the individual integrated steps of the catalytic
cycle, which are responsible for transporting substrates out of the membrane, are
still at large though a lot of researches in delineating the efflux mechanisms have
been done in the past [45, 115-117]. Notably, fusing membrane transporters with
EGFP will offer the opportunity to visualize them and thus to investigate their
interactions with substrates that lead to their extrusions. However, the fusion of
multi-drug efflux transporters with EGFP may disrupt their original efflux
functions. Therefore, it is crucial to first confirm that these fusion proteins still
maintain the original efflux functions prior to utilizing them to probe molecular
mechanisms of multidrug efflux pumps.
The past two decades have witnessed numerous uses of fluorescent
protein (e.g., GFP or its variants) in the study of localization and expression of
proteins in all kinds of organisms [23, 118-120]. For example, fusing promoter
region with fluorescent proteins has been used to identify the multidrug efflux
pump genes in Caenorhabditis elegans and to visualize the locations of MDR
transporters in fission yeast [24, 64], Besides, GFP has also been used as a
fluorescence probe to characterize the topologies of multidrug efflux transporters,
because

GFP

only

fluoresces

within

the

cytoplasmic

space

(reducing

environment), but not in the periplasm or plasma area [65]. Studies have shown
that GFP fusion proteins may alter the function of proteins. Unfortunately, the
lacking of the systematic studies on these areas is often the case [121].
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Functional studies of multidrug efflux pumps in bacterial and eukaryotic
cells often rely on measuring of the accumulation of radioactively labeled
substrates (14C and 3H) or the fluorescence dyes (e.g., rhodamine 123, Fluo-3,
Hoechst dyes) [68, 70]. Fluorescent dyes, such as Hoechst dyes and ethidium
bromide (EtBr), are particularly suitable for the study of the MDR mechanisms
because of the big increase of fluorescence intensities when they are changed
from aqueous solutions to non-polar and hydrophobic environments, especially
when the dye molecules intercalate with DNA. Therefore, change of timedependent fluorescence intensity of fluorescence dyes will reflect the real-time
state of the accumulation of substrates in bacterial and eukaryotic cells [71, 99].
Efflux functions of multidrug efflux pumps have also been characterized by
determining the minimal inhibitory concentrations (MICs) of antibiotics. These
antibiotics are specific substrates of these transporters and different strains have
demonstrated the different susceptibility towards them. For example, a wide
range of antibiotics such as chloramphenicol (CP), tetracycline (TET), gentamicin
(GM), aztreonam (AZT), rifampicin (RIF), ofloxacin (OFLX) and novobiocin (NOV)
have been utilized to detect the efflux functions of MexA,B-OprM efflux pump
and different P. aeruginosa strains showed different MICs of

the selected

antibiotics [13, 116].
In this study, we constructed

the

EGFP-mexB fusion

gene and

successfully expressed it in AMexB strain of Pseudomonas aeruginosa, thus
generating a new strain of Pseudomonas aeruginosa (MexA-EGFP-MexB-OprM).
To determine whether EGFP-MexB subunit can coordinate with other two pump
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components-MexA and OprM to form a complete efflux pump and retain its efflux
functions, we characterized the real-time

extrusion of fluorescence dye

molecules (EtBr) by these strains in the presence or absence of a MDR pump
inhibitor-CCCP using fluorescence spectroscopy. We also determined the
minimal inhibitory concentrations (MICs) of selected antibiotics such as AZT and
CP for these strains. To our knowledge, fusion of EGFP with MexB transporter in
Pseudomonas aeruginosa has not yet been reported and a functional EGFP
fusion strain can be used to study functions and structures of MexA,B-OprM
transporter in single living cells.

RESULTS AND DISCUSSION
Construction and characterization of EGFP-mexB fusion gene and its
expression
We designed and constructed the EGFP-mexB fusion gene by fusing
EGFP gene to the N-terminal of mexB gene and transformed the plasmid
containing fusion gene into the AMexB strain to create a new strain of
Pseudomonas aeruginosa (MexA-EGFP-MexB-OprMJ. The fusion

plasmid,

pMMB67EH-EGFP-MexB (67PB), is constructed as shown in Fig. 19 with details
as described in the experimental section. Briefly, the genomic DNA of
Pseudomonas aeruginosa was used to amplify mexB gene by a set of primers
(mexB P1 and mexB P2) while EGFP gene was amplified from pEGFP vector via
another set of primers (egfp P1 and egfp P2). Amplified EGFP and mexB PCR
products were then subject to a secondary round of PCR amplification by a set of

primers (egfp P1 and mexB P2). Then the PCR products of EGFP-mexB fusion
gene and vector (pMMB67EH) were then digested using a pair of restriction
endonuclease enzymes (Sa/l/H/ndlll). The digested PCR products (3,750 base
pairs, bp, EGFP-mexB gene) were finally ligated with the digested and purified
vector (8,800 bp), pMMB67EH. This approach enables us to insert EGFP-mexB
fusion gene into the vector to create the fusion plasmid (pMMB67EH-EGFPMexB, 67PB).
The amplified PCR products were characterized using routine agarose gel
electrophoresis and DNA sequencing. The results in Fig. 20A show that amplified
PCR products of mexB and EGFP are about 3,000 bp and 750 bp, respectively,
which agree well with the number of base pairs of the mexB and EGFP genes.
The fusion plasmid (pMMB67EH-EGFP-MexB, named as 67PB by us) in Fig. 19
was characterized using DNA agarose gel electrophoresis and DNA primer
walking sequencing. The fusion plasmid digested by Sa/l/H/ncflll (Fig. 20B)
showed two products of about 8,000 bp and 4,000 bp, which comply with
expected sizes of digested vector and EGFP-mexB fusion gene, respectively.
The DNA sequencing results of the fusion gene show that the sequences of the
mexB gene are identical with those reported previously [14, 15, 116, 122] and
that the EGFP gene is in same open reading form (ORF) with mexB gene without
any linking sequence between them.
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Fig. 19 Schematic illustrations of construction of EGFP-mexB fusion gene.
(A) The double and single stranded EGFP gene (step l-ll) was amplified from
plasmid pEGFP by a set of primers (egfp P1 and P2) and a single primer (egfp
P1), respectively. (B) The genomic DNA from wide type PA01 strain was used to
amplify double or single stranded mexB gene via a pair of primers (mexB P1 and
P2) and a single primer (mexB P2) (step l-ll), respectively. The amplified
products were further mixed and amplified by egfp P1 and mexB P2 primers
through asymmetrical PCR to get the fusion gene EGFP-mexB (A-B, step III). (C)
The fusion gene and vector (pMMB67EH) were digested by restriction enzymes
(Sa/l/H/ndlll). The digested fusion gene products were then ligated with the
digested vector, generating the fusion plasmid, pMMB67EH-EGFP-MexB (IV)
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Fig. 20 Characterization of EGFP-mexB fusion gene using agarose gel
electrophoresis.
A-L1: DNA markers/ladders in base pair (bp); L2: EGFP-mexB fusion gene
amplified using the mix of amplified EGFP and mexB gene products as a
template and egfp P1 and mexB P2 as primers; L3: mexB gene amplified using
the genomic DNA of P. aeruginosa strain (PA01) as a template and mexB P1
and P2 as primers; L4: EGFP gene amplified using the plasmid (pEGFP) as a
template and egfp P1 and P2 as primers. Arrows point to the PCR products of
about 750, 3,000 and 3,800 bp, which agree well with the number of base pairs
of EGFP, mexB and EGFP-mexB genes. B-L1: DNA markers in bp; L2:
pMMB67EH-EGFP-MexB plasmids are digested
endonuclease enzymes, Sal\/Hind\\\.

by a pair of restriction

Arrows point to the digested vector

plasmids of about 8,800 bp and EGFP-mexB fusion gene of about 3,800 bp
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Then we transformed the fusion plasmid (pMMB67EH-EGFP-MexB,
67PB) into the AMexB strain (the strain with deletion of the mexB gene) to create
a new strain of Pseudomonas aeruginosa (MexA-EGFP-MexB-OprM), and
characterized its expression in single living cells by measuring fluorescence of
EGFP in single living cells using fluorescence microscopy and spectroscopy. The
results in Fig. 21 show that nearly 100% of the MexA-EGFP-MexB-OprM cells
emit green fluorescence, but none of the wild-type strain (PA01), the efflux pump
overexpressed strain (NalB) and the pump deleted strain such as AMexB and
AMexA,B-OprM emit green fluorescence, demonstrating that the fusion gene are
successfully transformed and expressed in the AMexB cells.
Thus, the new strain enables characterization of locations, topologies and
functions of MexB component of MexA, B-OprM efflux pump in living cells, as
those reported for other MDR transporters [65]. However, In order to use them to
study the functions and structures of MexB proteins, we have to determine first if
EGFP-MexB plus MexA and OprM components can form a functional extrusion
pump.

Probing

of dependence

of efflux

kinetics of transporters on their

expression and the presence of pump inhibitor in live cells
Except from its use to label DNA fragment in molecular biological
experiments, EtBr is also a well-known substrate of MDR transporters (e.g.,
MexA,B-OprM) and has been widely used to monitor the accumulation and efflux
kinetics of these transporters [70, 99, 123, 124], Notably, the EtBr dye molecules
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emit weak fluorescence in aqueous solution (outside the cells), and their
fluorescence intensity increases substantially (up to 10-fold), as they permeate
into the cells and intercalate with DNA. Therefore, change of the fluorescence
intensity of the EtBr dye molecules has reflected the real-time accumulation and
efflux kinetics of multidrug efflux pumps in living cells.

Fig. 21 Characterization of expression of EGFP-mexB fusion gene in P.
aeruginosa.
(A) Dark-field optical images and (B) green fluorescence images of single living
cells: (a) PA01; (b) NalB; (c) AMexA,B-OprM; (d) AMexB and (e) MexA-EGFPMexB-OprM strains, respectively. Scale bar = 5 pm
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To determine whether EGFP-MexB protein expressed in the AMexB cells
can form a functional efflux pump with other components as MexA and OprM, we
first studied the efflux kinetics of the EtBr dyes by those different P. aeruginosa
strains containing different expression level of MexA,B-OprM pump proteins in
living cells in real time using the fluorescence spectroscopy.
We measured the time-dependent fluorescence intensity of the EtBr dye
molecules (10 and 40 pM) incubated with living cells (AMexB, MexA-EGFPMexB-OprM, PA01, NalB and AMexA,B-OprM; ODeoonm = 0.1) in PBS (pH=7.2)
over time. The results in Fig. 22 show that, the fluorescence intensity of the dye
molecules increases over time, indicating that the dye molecules enter the cells
and intercalate with intracellular DNA.

Notably, the accumulation rates highly

depend upon the expression level of MexA,B-OprM pump proteins. The results in
Fig. 22A and B all show that the highest accumulation rate of the intracellular dye
molecules with the highest fluorescence intensity was found in AMexA,B-OprM
cells (deletion of MexA,B-OprM), while the lowest accumulation rate was
observed in NalB cells (MexA,B-OprM pump overexpressed strain), regardless of
the concentration of EtBr dyes used. The MexA-EGFP-MexB-OprM fusion strain
only shows a slightly lower accumulation rate of dye molecules than the AMexB
strain (deletion of MexB), suggesting that fusion of MexB with EGFP fails to
restore the efflux function of MexB antiporter fully. This could be due to steric
hindrance effects of fusing EGFP with MexB gene. In addition, the accumulation
rate of dye molecules in the PA01 strain (Normal expression of MexA,B-OprM) is
lower than that in the fusion strain (MexA-EGFP-MexB-OprM).
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Fig. 22 Study of the dependence of efflux kinetics of the intracellular dye
molecules on the expression of MexA,B-OprM transporter in live cells.
Time-dependent fluorescence intensity of different concentrations (A-10pM, B-40
pM) of EtBr dye molecules incubated with cells
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= 0. 1 in PBS, pH 7.2)

over time: (a) AMexA, B-OprM, (b) AMexB, (c) MexA-EGFP-MexB-OprM (d)
PAOl and (e) NalB strains
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Interestingly, the WT PA01 strain shows a slightly lower accumulation rate
than the AMexB or fusion strain (MexA-EGFP-MexB-OprM) does, especially in
the presence of 10pM EtBr dyes and this leads us to question whether it is
enough to probe the function of MexA,B-OprM efflux pump just by monitoring the
accumulation rates of EtBr dye molecules. The results we observed in this study
might be due to the interplay of OprM with other MDR pump components such as
MexX, MexY to form another MDR transporter (MexX,Y-OprM). Besides, other
MDR

pumps

like

MexC,D-OprJ,

MexE,F-OprN

and

MexH,l-OprD

in

Pseudomonas aeruginosa could also extrude EtBr dyes [5, 47],
In addition, we also studied the effects of a PMF (proton motive force)
inhibitor, CCCP, on the accumulation of intracellular EtBr dye molecules. The
results in Fig. 23 demonstrated that in the presence of 0.1 mM CCCP [125], all
strains have increased accumulation of EtBr dye molecules inside cells. This
indicated that CCCP can inhibit the efflux function of MexA,B-OprM pump. But,
the inhibitory effects are not specifically on this pump since the accumulation of
EtBr dyes in AMexA,B-OprM strain also increased in the presence of CCCP. This
could be due to the inhibitory effects of CCCP on other MDR pumps using PMF
as energy sources such as MexC,D-OprJ and MexE,F-OprN.

Minimum inhibitory concentrations (MICs) of antibiotics for different
Pseudomonas aeruginosa strains
P. aeruginosa has been reported to have intrinsic antibiotic resistance
against a wide range of antibiotics such as chloramphenicol (CP), tetracycline
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Fig. 23 Probing of inhibitory effects of a pump inhibitor (CCCP) on efflux
function of M exA ,B -O p rM and MexA-EGFP-MexB-OprM transporters in live
cells.
Time-dependent fluorescence intensity of the dye molecules (EtBr; 15 pM),
incubated with cells (OD6oo nm = 0.1 in PBS, pH 7.2): (A) AMexA,B-OprM, (B)
AMexB, (C) MexA-EGFP-MexB-OprM, (D) PA01 and (E) NalB, in presence (a)
and absence (b) of CCCP (0.1 mM)
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(TET), azthreonam (AZT), gentamicin (GM) [5, 17, 112, 126,127],
To further access the efflux function of the fusion strain (MexA-EGFPMexB-OprM), we determined the MICs of two sensitive antibiotics (CP and AZT)
for five mutant strains. The results in Table 3 indicate that the fusion strain
partially restored the efflux function of MexA,B-OprM pump as is shown by the
very small difference between the MICs of AZT and CP in the mutant lacking
MexB (MIC of AZT- 0.2 pg/mL and MIC of CP- 4 pg/mL) and those in the EGFP
fusion strain (MexA-EGFP-MexB-OprM; MIC of AZT- 0.5 pg/mL and MIC of CP8 pg/mL). However, there is a substantial difference between the MICs of AZT
and CP in the EGFP fusion strain and those in the PA01 or NalB strain. For
instance, MICs of AZT and CP in the PA01 strain are 25 and 3.13 pg/mL,
respectively, while those in the NalB strain are 100 and 15.7 pg/mL, respectively.

Table 3 MICs of CP and AZT in different Pseudomonas aeruginosa strains
Strains

Properties

PAO4290
TNP082
TNP071
TNP076
EGFP Fusion

PA01 (WT)
NalB (Overexpression)
AMexB
AMexA.B-OprM
MexA-EGFP-MexB-OprM

MIC (pg/mL)
AZT
CP
25
100
4
1.56
8

3.13
15.7
0.2
0.2
0.5

Reference
_

r a

[13]
a i

Structural modeling of the MexA-EGFP-MexB-OprM multidrug efflux pump
Initial coordinates of the complete trimeric pump were obtained from the
data-driven docking of AcrA-TolC onto AcrB [128], The individual components of
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the tripartite multidrug efflux pump from P. aeruginosa are highly homologous to
the corresponding components in the MexA,B-OprM transporter system with up
to 69 % sequence identity between the antiporter AcrB and MexB [84], Three
dimensional structure alignment showed low average RMSDs for coordinate
displacements of 2.053 A for AcrA/MexA (PDB codes: 2F1M and 1VF7), 2.355 A
for AcrB/MexB (PDB codes: 2J8S and 2V50) and 2.064 A for TolC/OprM (PDB
codes: 2VDD and 1WP1) [129, 130]. The working model was assembled by
secondary structure matching of MexB on AcrB in its trimeric configuration [91,
130]. The EGFP model was assembled separately using SWISS-MODEL [85],
based on 3D structure of the GFP (PDB code: 3 0 G 0 ) with a sequence identity of
98.7%. Secondary structures prediction [86] showed the linker region connecting
the C-terminus of the EGFP domain to the N-terminus of MexB to be
unstructured. The connecting residues were built manually using program Coot
[91]. The EGFP domains were positioned in the cytoplasmic space with no
clashes to the MexB domains and the membrane region. All Figures (Fig. 24A-B)
were generated using PyMOL [92].
Fig. 24A shows the assembled MexA-MexB-OprM model based on the
coordinates of the data-driven docking model of the multidrug efflux pump AcrAAcrB-TolC from P. aeruginosa [128]. The model shows the location of the MexB
N-termini at the cytosolic end of the translocation pore of the transporter system
with the unstructured loop of the N-termini pointing inward towards the trimeric
pore.

Outer Membrane
outer membrane channel

Penplasma
MexA membrane fusion protan

MexB antiporter

Inner Membrane
EGFP Nt-fuaon protein

Cytoplasma

(a)

W f>

(b)

Fig. 24 Structural analysis of the assembled MexA-MexB-OprM and MexAEGFP-MexB-OprM trimers.
(A) Bottom view of the assembled MexA-MexB-OprM trimer. The membrane
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fusion protein MexA and the outer membrane channel OprM are shown in
turquoise and violet, respectively. The individual antiporter MexB monomers are
depicted in red, orange and light brown. Black O rings point to the position of the
N-termini of the MexB monomers at the end of the N-terminal loop pointing
towards the translocation pore of the trimeric antiporter; (B) Side (a) and bottom
(b) view of the proposed model of the MexA-EGFP-MexB-OprM trimer

Fig. 24B shows the EGFP domains fused to the N-terminal of MexB in its
trimer assemblage. Spatial placement of the EGFP domains in the cytosol is
limited by potential EGFP to EGFP, or EGFP to MexB clashes in the trimeric
configuration (Fig. 24B). The position and orientation of the N-terminal fused
EGFP domains may either partially block the translocation pore, or restrict the
movement of the individual pump domains thereby restricting efflux activity.

SUMMARY
In summary, we have designed and constructed a EGFP-mexB gene and
successfully expressed the fusion gene in the AMexB strain to generate a new
strain of Pseudomonas aeruginosa (MexA-EGFP-MexB-OprM). We studied the
dependence of accumulation kinetics of intracellular fluorescence molecules
(EtBr, a pump substrate) on the expression level of MexA,B-OprM pump proteins
for each of the strains (PA01, NalB, AMexB, MexA-EGFP-MexB-OprM and
AMexA,B-OprM), by measuring the time-dependent fluorescence intensity of the
intracellular dye molecules using fluorescence spectroscopy. We found that

MexA-EGFP-MexB-OprM can extrude the pump substrate (EtBr). However, there
is no big difference in terms of the accumulation rate of intracellular fluorescent
dyes between the fusion strain and the AMexB strain. Besides, CCCP was
shown to inhibit the efflux pumps in all the tested strains. Also Minimum Inhibitory
Concentration (MIC) studies of two selected antibiotics in these two strains
yielded outcomes of only about two times of differences. These results all
suggest that the fusion strain partially restores the efflux function of MexA,BOprM transporter, even though we observed the positive interaction between
EGFP part of fusion protein with Ag nanoparticle based bio-sensor during the in
vitro experiment (Data not shown). Putative structural analysis shows a possible
obstruction of the EGFP part to the MexB one, resulting in conformational
hindrance, which may obstruct MexB to coordinate with MexA and OprM to form
a completely functional efflux pump.
Work is in progress to create the new strains for probing molecular
mechanisms and structures of the MexA,B-OprM multidrug resistance efflux
pump. Future work can be done on the fusion of GFP variants (RFP and CFP) to
other two subunits (MexA and OprM). The Fluorescence Resonance Engery
Transfer (FRET) study between either of two or three subunits of MexA,B-OprM
efflux pump can be performed as well to study the interplay between them.
Those future studies combined with utilization of nanoparticle based optical
sensors to probe the efflux functions of this MDR transporter will provide more
insights into its molecular mechanisms. However, it remains a challenge to get
three fully functional fusion proteins [113,114],
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METHODS
Reagents and cell strains
PCR polymerase (Agilent Technologies), plasmid isolation kit (Qiagen),
DNA gel extraction kit (Qiagen), DNA ligation kit (Roche) which includes ligation
enzyme (T4 DNA ligase) and ligation buffer, Sall/Hindlll (NEB), Tetracycline
(Calbiochem), Chloramphenicol (Calbiochem), IPTG (GBT), CCCP (carbonyl
cyanide-m-chlorophenylhydrazone,

£ 97%,

Sigma),

Carbenedllin

(Sigma),

Aztreonam (Sigma), ethidium bromide (Invitrogen), and E. coli DH5a (Invitrogen)
were purchased and used as received.

P. aeruginosa strains (WT, NalB1,

AMexB, AMexA,B-OprM) and plasmid (pMMB67EH) were provided by Hiroshi
Yoneyama [131, 132]. All other reagents except indicated were purchased from
Sigma and used as received. The nanopure deionized (Dl) water (18 MQ water,
Barnstead) was used to prepare all solutions.

The L-broth (LB) medium (1%

tryptone, 0.5% yeast extract and 0.5% NaCI in Dl water, pH = 7.2) was prepared.

Design and construction of EGFP-mexB fusion gene
We fused N-terminal of mexB gene with C-terminal EGFP to prepare the
EGFP-mexB fusion gene by asymmetrical PCR amplification, and then inserted it
into the vector (pMMB67EH) to prepare pMMB67EH-EGFP-MexB vector [133].
We first used one pair of egfp primers (egfp primer-1: 5’-CTT GTC GAC AAG
GGG ATC CAC CAT GGT GAG CAA GG-3’ and egfp primer-2: 5'-CAA TGA
AAA ACT TCG ACA TCT TGT ACA GCT CGT CCA TGC-3’) and EGFP plasmid
as a template to amply EGFP gene.

We then used only egfp primer-1 and
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amplified double stranded EGFP gene as the template to create the coding
strand of EGFP gene (ss-egfp). Using the similar approaches, we used one pair
of mexB primers (mexB primer-1: 5’-GCA TGG ACG AGC TGT ACA AGA TGT
CGA AGT TTT TCA TTG-3’, mexB primer-2: 5’-GAT AAG CTT ATC ATT GCC
CCT TTT CGAC-3’) and genomic DNA of P. aeruginosa as the template to
generate and amplify the mexB gene. We used mexB primer-2 and the amplified
double stranded mexB genes as the template to generate and amply the
template strand of mexB gene (ss-mexB), which has 20 bases that are
complimentary to the ss-egfp at the 3’ ends.

By mixing the ss-egfp with ss-

mexB, it creates 20 bp double stranded DNA, that links the ss-egfp with ssmexB, which is used as the template to generate and amply egfp-mexB fusion
gene using both egfp primer-1 and mexB primer-2 as primers.

The PCR

products of the egfp-mexB fusion gene were characterized by agarose gel
electrophoresis (0.8%, E = 8-10 V/cm), and purified by the gel purification kit
(Qiagen).

The

purified

PCR

products

of

EGFP-mexB

genes

and

vector

(pMMB67EH) were digested by a pair of restriction enzymes (Sa/l/H/ndlll), which
was carried out by incubating the PCR products (10 ng) or the vector (5 ng) with
two units of SalUHindlW each in the presence of 10x digestion buffer (4 or 3 pL) in
Dl water (40 or 30 pL) at 37 °C for 3 h, respectively. The digested products were
characterized by the agarose gel electrophoresis and purified via the gel
extraction kit.

After purification, the digested and purified EGFP-mexB genes

were ligated into the same treated vector (pMMB67EH) to produce pMMB67EH-
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EGFP-MexB. The ligation was carried out by incubating digested and purified
EGFP-mexB fusion genes (20 nM) with digested and purified vector (5 nM) in the
presence of one unit of T4 DNA ligase and 10x ligation buffer (2 pL) in Dl water
(20 pL) at 12 °C overnight. All digestion, gel electrophoresis and ligation work
are carried out using standard protocols [134].

The pMMB67EH-EGFP-MexB was then transformed into DH5a competent
cells (Invitrogen). Briefly, we mixed the pMMB67EH-EGFP-MexB (10 pL, 0.1
pg/pL) with the competent cell suspension (100 pL, 2x107cells/mL), placed the
mixture on ice for 30 min, followed by a heat shock at 42 °C for 90 s, then placed
it back onto the ice for another 2 min. We then added the LB media (1 mL) to the
mixture, incubated it in a shaker (LabLine Orbit-Environ, 37 °C, 200 rpm) for 1 h,
and centrifuged the solution at 5000 rpm for 5 min. We removed the supernatant
and suspended the pellets (transformed cells) in the fresh medium, spread them
onto LB agar plates (0.5% yeast extract, 0.5% NaCI, 1% tryptone,1.5% agar and
100 pg/ml ampicillin) and incubated the plates at 37 °C for 24 h.

Positive

ligations were verified by restriction enzyme digestion (Sal\/Hind\\\), PCR
amplification with use of primers (egfp primer-1 and mexB primer-2), and DNA
sequencing (Applied Biosystem, 3730x1 DNA Analyzer).

Plasmid with the correct sequence was finally transformed into MexB
deleted strain (AMexB) using electroporation [135-138].

Briefly, the cells

(AMexB) were cultured in the LB media under shaking at 37 °C until they reach
the early log phase (OD6oo nm - 0.3-0.5). The cells were then harvested using

centrifugation (7000 g, 10 min, 4 °C), and washed with the sucrose (300 mM)
three times, and resuspended in the sucrose. The cell suspension was placed
on ice for 30 min before electroporation. We then mixed the competent AMexB
cells (80 pL) with the fusion plasmid (pMMB67EH-EGFP-MexB, 10 pL, 1 pg/pL),
transferred them to a pre-chilled sterile electroporation cuvette (gap between two
electrodes = 0.2 cm), and applied the electric pulses (2.5 kV, 25 pF, 5 ms)
(Biorad Gene Pulser). The cells were then cultured in the LB medium (3 mL) in
the shaker (200 rpm, 37 °C) for 2 h, and harvested using centrifugation (5000
rpm, 5 min).

The cells were streaked onto the LB agar plate containing 100

pg/ml carbenecillin, which was then incubated at 37 °C for 24 h. The clones
were picked and cultured at 37 °C in the LB medium with 100 pg/mL carbenecillin
to produce EGFP fused cells, MexA-EGFP-MexB-OprM.

Cell Culture and Assay
We pre-cultured each of five strains of P. aeruginosa: WT, NalB1, AMexB,
AMexA,B-OprM, and MexA-EGFP-MexB-OprM, by inoculating a single clone of
each strain from the LB agar plates into the LB medium and placed them in the
shaker (37 °C, 200 rpm) for 12 h.

We then cultured the cells in the fresh LB

medium in the shaker (37 °C, 200 rpm) for another 8 h, except adding 2 mM
IPTG and 100 pg/mL carbenecillin in the medium for the culture of MexA-EGFPMexB-OprM cells to induce the expression of the fusion protein as the OD6oo nm
(optical density, absorbance, at 600 nm) of the cell suspension reaches 0.5. We
harvested the cells using centrifugation (Beckman J2-21, JA-14 rotor, 6000 rpm,
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23 °C , 10 min), washed them with the PBS buffer (50 mM phosphate, 100 mM
NaCI, pH 7.0) three times, and resuspended them in the buffer. The cell
concentration in the buffer (OD6oo nm = 0.1) was used to characterize the
expression of the fusion protein (EGFP-MexB) in single live cells using
fluorescence microscopy and to study the efflux function of membrane
transporters by measuring accumulation kinetics of EtBr dyes in the cells using
fluorescence spectroscopy.

Characterization of expression of fusion gene in single living cells using
fluorescence microscopy
The cells suspended in the PBS buffer were imaged in a microchamber
using dark-field optical microscopy and epi-fluorescence microscopy (Nikon, E400) equipped with a CCD camera (Micromax, Roper Scientific) [71, 75, 90].
The design and construction of the microchamber and dark-field optical
microscopy for imaging of single cells were fully described in our previous studies
[71, 90]. In this study, the fluorescence filter cube (Chroma Tech) containing a
band-pass excitation filter (455 ± 30 nm), band-pass emission filter (525 ± 30 nm)
and a dichroic mirror (500 nm), was used for imaging expression of EGFP-MexB
fusion protein in the strain (MexA-EGFP-MexB-OprM). The dark-field optical
microscope is equipped with a dark-field condenser (Oil 1.43-1.20, Nikon) and a
10Ox objective (Nikon Plan fluor 100xoil, iris, SL. N.A. 0.5-1.3, W.D. 0.20 mm).
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Fluorescence spectroscopic study of transport of EtBr dye molecules in
living cells
Fluorescence intensity of EtBr (10 and 40 pM) incubated with the cells
(O D

6o o n m = 0.1) in the PBS buffer in the presence or absence of 0.1 mM CCCP

were acquired over time (1-2 h) with 3-s time interval at room temperature using
a fluorescence spectrometer (Perkin-Elmer, LS50B). The excitation and emission
wavelengths were selected at 465 and 600 nm with a width of each slit at 10 nm,
respectively.

Minimum inhibitory concentration (MIC) studies for different Pseudomonas
aeruginosa strains
We measured the MICs of two representative antibiotics (AZT and CP)
toward the cells: WT, NalB1, AMexB, MexA-(EGFP-MexB)-OprM, and AMexA.BOprM.

Each strain was pre-cultured by inoculating a single clone from the LB

agar plates into the LB medium (add 100 pg/mL carbenecillin for culturing the
EGFP fusion strain to maintain the plasmid) and shaken overnight (200 rpm, 37
°C).

The cell suspension (100 pi, ~104 cells) was added into the fresh LB

medium (2.9 mL) in the presence of a set of different concentrations of AZT or
CP (add 100 pg/mL carbenecillin and 2 mM IPTG in the culture of the fusion
strain to induce the expression of fusion protein), and shaken for another 16 h
(200 rpm, 37 °C). The concentration and number of the cells for each cultured
strain was measured using the UV-visible spectroscopy
microscopy, respectively.

(O D

6o o n m ) and dark-field
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CHAPTER V
SIZE-DEPENDENT ANTIBACTERIAL EFFECTS OF SILVER
NANOPARTICLES CONJUGATED ANTIBIOTICS ON GRAM-NEGATIVE
BACTERIA, PSEUDOMONAS AERUGINOSA

INTRODUCITON
The development of nanotechnology presents us new therapeutic and
diagnostic concepts in a wide variety of biological and medical processes. Due to
their unique characteristics,

nanoparticles are considered to

have wide

applications in biosensing [139], bioimaging [140] and targeted drug delivery
[141]. For example, nanoparticles are used to enhance oral delivery by improving
the solubility of poorly absorbed drugs [142]. They are capable of penetrating the
cells to help cellular internalization and connective tissue permeation, thus
delivering the drugs efficiently to the targeted tissue without clogging capillaries
[143, 144], The basic requirements for targeted drug delivery are that the carrier
should be circulated extensively in the bloodstream, it must be small enough to
access target tissues and target cells, it has to be capable of delivering the
loaded cargos into the cells, and following endocytosis, it must be able to escape
endosome-lysosome

processing.

Different

types

of

nanoparticles

with

biomedical relevance such as polymeric nanoparticles, dendrimers, liposomes,
quantum dots, metal nanoparticles, etc. have been extensively studied in the
past [145]. Of them, noble particles like Ag or Au

NPs have been used to

delivery protein-based drugs and are of particular utility because the unique
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optical, chemical and electronic properties of noble NPs made them well suited
for biomedical sensing, therapeutic drug delivery [26, 44, 71, 90, 97, 145].
With significant developments in the understanding of nanosystems,
research efforts are focused on integrating them with biology. Resistance of
bacteria to bactericides and antibiotics has been a research subject of great
interest due to the development of multidrug resistant strains [2, 9, 12, 17]. The
resistance to bactericides or antibiotics is largely because of active efflux of
antibiotics outside cells by multidrug resistance (MDR) transporters on the
membranes [1-12, 45, 46, 56, 62, 146]. Numerous researchers have explored the
feasibility and efficiency of using nanomaterials as new drug carriers. For
instance, Gu et al. reported the enhanced antimicrobial effects of nanoparticles
conjugated with vancomycin [147],

Grace et al. used the gold nanoparticles

conjugated with drugs and investigated their antimicrobial effects in various types
of organisms [148].

Other researches also characterized the enhanced

antibacterial effects of drug conjugated silver nanoparticles [149-151], All these
research results demonstrated enhanced antibacterial effects of nanoparticles
when

conjugated with

different drugs, which

raises hopes

in applying

nanoparticles as effective drug carriers for the specific targeting and treatment of
many MDR related diseases. While there were many reports about the delivery
of different drugs in nanoparticle conjugated forms, little efforts were made, so
far, to determine how the sizes of nanoparticle carriers would impact on the
efficiency of antibiotic therapies.

Hence, in this study, we compared the therapeutic efficiency and
biocompatibility of AgMUNH2-OFLX NPs with respect to their carrier sizes (2.4 ±
0.7 nm, 13.0 ±3.1 nm and 92.6 ± 4.4 nm) and drug free forms (OFLX). Notably,
we found the size-dependent antimicrobial effects of silver NPs conjugated
antibiotics (OFLX) on gram-negative bacteria, P. aeruginosa, which were that
larger sized NPs conjugated antibiotics generated higher inhibitory effects
against the growth of bacteria than smaller sized NPs conjugated antibiotics at
the same concentration of conjugated antibiotics and two of larger sized NPs
conjugated antibiotics showed lower MIC values than their drug free forms. Thus
our results offer new insights into design of more effective drug delivery vehicles
and suggest that antibiotics conjugated with silver NPs might be used in therapy
for better treatment of multidrug resistance associated diseases.

RESULTS AND DISCUSSION
Synthesis and characterization of different sized silver (Ag) nanoparticles
First, we have synthesized three sized Ag NPs (2.4 ± 0.7 nm, 13.0 ± 3.1
nm and 92.6 ± 4.4 nm) according to the methods described in the experimental
section. Next, we characterized these three sized Ag NPs using UV-visible
spectroscopy (Fig. 25A) and the results demonstrated that 2.4 ± 0.7 nm silver
NPs showed the peak of wavelength at 392 nm (Fig. 25A, I), while 13.0 ± 3.1 and
92.6 ± 4.4 nm Ag NPs showed the peak wavelengths at 398 nm (Fig. 25A, II) and
482 nm (Fig. 25A, III), respectively. We also characterized their sizes using high
resolution transmission electron microscopy (HRTEM) (Fig. 25B) and the
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corresponding histograms of size distribution of each sized Ag NPs (Fig. 25C)
showed that the average diameters of three sized Ag NPs are 2.4 ± 0.7, 13.0 ±
3.1 and 92.6 ± 4.4 nm, respectively. Taken together, those results are quite
consistent with our previous studies [38, 42, 43],

Conjugation of ofloxacin (OFLX) to Ag NPs and characterization of Ag
carriers by UV-visible spectroscopy
After synthesis of three sized Ag NPs, they were coated with MUNH2
groups first before linking with the drug molecules (OFLX). After conjugation,
OFLX conjugated NPs solutions were centrifuged and washed extensively to
remove any unbound drug molecules. Successful conjugation was verified by the
red shift in the UV-visible spectra before and after conjugation. As shown in Fig.
26A-C, the UV-visible spectra of each sized Ag, AgMUNH2, AgMUNFh-OFLX
NPs all showed a red-shift of peak wavelength as Ag NPs (Fig. 26A-C, a) are
conjugated with MUNH2 groups first (Fig. 26A-C, b). Then, there were another
red-shift of peak wavelength and the emergence of the peak wavelength of OFLX
at around 325 nm as each sized AgMUNH2 NPs were finally linked with OFLX
molecules (Fig. 26A-C, c). All these results suggest that each sized Ag NPs are
successfully conjugated with MUNH2 groups and OFLX drug molecules step by
step. [For abbreviation, Ag, AgMUNH2, AgMUNH2-OFLX NPs of three sizes will
be named as 2.4 nm Ag carriers (A), 13.0 nm Ag carriers (B) and 92.6 nm Ag
carriers(C), respectively].
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Fig. 26 Characterization of three sized Ag, AgMUNH2and AgMUNH2-OFLX
NPs by UV-visible spectroscopy.
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Characterization of Ag, AgMUNH2 and AgMUNH2-OFLX NPs by DFOMS and
LSPR Spectroscopy
Aside from the characterization of Ag, AgMUNH2, AgMUNH 2 -OFLX NPs
by UV-visible spectroscopy as shown above, we also characterized them using
our Dark Field Optical Microscopy Spectroscopy (DFOMS) system [37, 38, 4244, 98]. In addition, we measured the representative LSPR spectra of each sized
Ag, AgMUNH2 and AgMUNH2-OFLX NPs using our Nuance multispectral
imaging system (CRI).
Fig. 27 showed the representative dark field images and LSPR spectra of
each sized Ag, Ag MUNH2 and AgMUNH2-OFLX NPs. As shown in Fig. 26, for
each sized Ag carriers, the peak wavelengths of Ag carriers start to shift into red
direction as Ag NPs are conjugated with MUNH2 groups and followed by another
red shift when AgMUNH2 groups are linked with OFLX drug molecules. In
consistence with the above UV-visible spectra results, we also found that the
peak wavelengths of representative LSPR spectra of each sized Ag, AgMUNH2,
AgMUNH2-OFLX NPs showed a stepwise red shift from Ag NPs to AgMUNH2
NPs, and to AgMUNH2-OFLX NPs as depicted in Fig. 27, which showed
representative dark-field images and LSPR spectra of 2.4 nm (A), 13.0 nm (B)
and 92.6 nm (C) Ag carriers, respectively. The dark-field images of each type of
Ag carriers are in the order of Ag (a), AgMUNH2 (b) and AgMUNH2-OFLX (c)
NPs and the corresponding LSPR spectra of Ag carriers (d, i-vi) are shown as
labeled in Fig. 27A-C, a (i-ii), b (iii-iv) and c (v-vi).
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For instance, 2.4 ± 0.7 nm Ag NPs in Fig. 27A-a are mostly blue and they
will appear greenish when they are conjugated with MUNH2 groups (Fig. 27A-b)
and even more greenish in AgMUNH 2 -OFLX NPs (Fig. 27A-c). Besides, the peak
wavelengths of representative LSPR spectra of 2.4 nm Ag carriers also showed a
red shift from Ag NPs to AgMUNH2 NPs, and to AgMUNH2-OFLX NPs (i-vi of Fig.
27A-d). The other two sized Ag carriers have also shown a stepwise red shift in
the peak wavelengths of representative LSPR spectra from bare Ag NPs to
AgMUNH2 NPs, and to AgMUNH2-OFLX NPs as shown in Fig. 27B and C (Fig.
2 7 B -13.0 nm Ag carriers, Fig. 27C- 92.6 nm Ag carriers).
Those above results demonstrated that each sized Ag NPs were
successfully synthesized and conjugated with MUNH2 groups and OFLX
molecules step by step, and their optical properties were also well characterized
by UV-visible spectroscopy, DFOMS and LSPR spectroscopy.

Calculation of conjugation ratios of OFLX molecules to AgMUNH2 NPs in
each sized AgMUNH2-OFLX NPs
Briefly, the standard UV-visible spectra curves of OFLX alone at different
concentrations were obtained first to calculate the extinction coefficient of OFLX
solution. Then, the concentration of conjugated OFLX molecules in each sized
AgMUH2-OFLX NPs was calculated from the net spectra of conjugated drugs by
subtracting

the

UV-visible

spectra

of

AgMUNH2-OFLX

and

AgMUNH2

nanoparticle solution of the same concentrations. After that, the conjugation
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Fig. 27 Characterization of three sized Ag, AgMUNH2 and AgMUNH2-OFLX
NPs by DFOMS and LSPR spectroscopy.
Representative dark-field images and LSPR spectra of 2.4 nm (A), 13.0 nm (B)
and 92.6 nm (C) Ag carriers, respectively. Dark-field images of bare Ag NPs (a),
AgMUNH2 NPs (b) and AgMUNH^OFLX (c) NPs and representative LSPR
spectra (d) of single Ag, AgMUNH2, AgMUNH2-OFLX NPs (i-ii: Ag NPs, iii-iv:
AgMUNH2 NPs, v-vi: AgMUNH2-OFLX NPs )
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ratios of OFLX molecules to AgMUNH2 NPs for each sized AgMUNH 2 -OFLX NPs
(Table 4) are calculated from dividing the concentration of conjugated OFLX
molecules by the concentration of that sized AgMUNH 2 -OFLX NPs solution.
As shown in Table 4, the conjugation ratios of OFLX molecules to single
AgMUNH2 NP in AgMUNH2-OFLX NPs are 863:1, 9435:1 and 652941:1 for the
2.4 nm, 13.0 nm and 92.6 nm sized AgMUNFh-OFLX NPs, respectively.

Table 4 Calculation of conjugation ratios of ofloxacin (OFLX) molecules to
each AgMUNH2 nanoparticle in each sized AgMUNH2-OFLX NPs

AgMUNH2OFLX
Diameter
(nm)

AgMUNH2OFLX
concentration
(nM)

Net
absorbance
of OFLX at
288 nm

Concentration
of conjugated
OFLX (pM)

Conjugation
ratio of OFLX
to AgMUNH2

2.4

50

0.337

43.152

863.0

13. 0

3.3

0.243

31.136

9435.0

92.6

0.02975

0.152

19.425

652941.8

a
b

Amax = 288 nm

e (1/uM cm), 288 nm = 0.0078

Stability study of AgMUNH2-OFLX NPs in modified LB medium
Stability studies of each sized AgMUNH2-OFLX NPs in the culture medium
are very crucial prerequisites for further assessment of the antibacterial efficiency
of these NPs. Preliminary studies indicated all three sized AgMUNH2-NPs are
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not stable in the LB medium (data not shown), so we modified the LB medium.
To study the stability of NPs in the modified medium, we determined the number
of single NPs using DFOMS as described previously [38, 39]. The concentrations
of each sized AgMUNH2-OFLX NPs used here were 6 nM, 0.08 nM and 7 pM for
2.4, 13.0 and 92.6 nm AgMUNH2-OFLX NPs, respectively (Note that for each
sized NPs, the concentration used to study their stabilities in the culture medium
here was much higher than that required for the later MIC experiments). A
minimal of 20 images at each time point from representative locations for each
experiment was acquired and the experiment was repeated three times. Results
were shown in Fig. 28A-C, which represented the average number of AgMUNH2OFLX NPs per image versus time in modified LB medium for 2.4 nm, 13.0 nm
and 92.6 nm sized AgMUNH2-OFLX NPs, respectively.
Notably, for each sized AgMUNH2-OFLX NPs (2.4 nm, 13.0 nm and 92.6
nm, respectively), the average number of NPs per image versus time remained
unchanged over 24 h of incubation (Fig. 28A-C). This indicated that all sized
particles were stable in the modified LB medium for at least 24 hrs at the studied
concentrations. These positive results paved the way for further utilization of
these silver nanoparticles conjugated antibiotics in gram-negative Pseudomonas
aeruginosa cells in order to asses their potential antibacterial effects by
measuring the MIC values of silver nanoparticles conjugated OFLX compared to
their free forms in different P. aeruginosa strains containing different level of
expression of the MexA,B-OprM pump proteins (Wide type - PAOl and MexA,BOprM efflux pump deleted strain - AMexA,B-OprM).
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Fig. 28 Stability study of three sized AgMUNH2-OFLX NPs in modified LB
medium for over 24 hrs by DFOMS.
Results are shown as the average number of particles per image taken from a
high resolution color camera for each sample prepared in a micro-channel slide.
Concentrations of three sized AgMUNH2-OFLX NPs used in this study are 6nM,
0.8 nM and 7 pM for 2.4 nm (A), 13.0 nm (B) and 92.6 nm (C) sized AgMUNH2OFLX NPs, respectively
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Besides, we also studied the stability o f those AgMUNH 2 -OFLX NPs in
modified LB medium by UV-visible spectroscopy [38, 39, 97, 98], As shown in
Fig. 29, the UV-visible spectra of each sized AgMUNH2-OFLX solution remain
the same over 24 h of incubation. Combining the results of stability studies by
DFOMS above and UV-visible spectroscopy, all indicated that three sized
AgMUNH2-OFLX NPs are stable in the modified LB medium over the 24 hrs of
time.

Cells function properly in the modified LB medium
After we verified that three sized AgMUNH2-OFLX NPs are stable in the modified
LB medium for at least 24 hrs, our next step would be to check the efflux
functions of different P. aeruginosa strains in the modified LB medium. We used
the time course incorporation of fluorescent dyes (EtBr, 10 pM) to probe the
efflux functions of different P. aeruginosa strains as previously studied [38, 99].
As shown in Fig. 30, for each of strains, efflux kinetics of EtBr molecules by each
of three P. aeruginosa strains were nearly the same in both LB medium (A) and
modified LB medium (B), with the highest accumulation of intracellular EtBr
molecules in the pump deleted strain (AMexA,B-OprM), followed by a moderate
accumulation of Etbr in wide type strain (PA01) and the lowest accumulation of
EtBr in the pump overexpressed strain (NalB). This indicated that modified LB
medium was fully capable of maintaining original efflux functions of these strains.
Those results are quite consistent with previous studies from our and other
groups [38, 71, 73, 99].
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Next, we did the cell live / dead viability assay at the end of cell function
studies to see if the number of viable or dead cells grew in these two mediums is
approximately the same as previously studied [37, 38]. Fig. 31A-B showed the
representative dark-field and fluorescence images of cells in this viability assay,
more than five hundred cells from multiple images are used to calculate the
number of viable cells for each strain in either regular or modified LB medium.
As shown in Fig. 31C, for each of three P. aeruginosa strains, the number of
viable cells in two types of LB mediums is nearly the same (about 98%).

Size dependent antimicrobial effects of AgMUNH2-OFLX NPs in different P.
aeruginosa strains
To investigate the antimicrobial effects of AgMUNH2-OFLX NPs in P.
aeruginosa cells, MICs of AgMUNH2 conjugated OFLX were determined for each
sized NPs with the respective free forms of OFLX and corresponding AgMUNH2
NPs as controls. At the end of the experiment, bulk images of glass tubes for
each group of nano-carriers were taken as shown in Fig. 32-34 for PA01 and
AMexA,B-OprM strains, respectively. Those images clearly demonstrated that
92.6 nm sized AgMUNH2 NPs conjugated OFLX molecules generated the
highest antibacterial effects followed by 13.0 nm and 2.4 nm sized AgMUNH2
NPs conjugated OFLX at the same concentration of conjugated OFLX molecules,
no matter which strain was used.
Optical densities at 600 nm of samples in each glass tube were measured
and results were plotted against the concentrations of conjugated OFLX
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molecules as shown in Fig. 34. The MIC curves showed the same trend of
antimicrobial effects generated by different sized AgMUNH2-OFLX NPs as we
observed from the glass tube images in Fig. 32-34, which is that larger sized
AgMUNH2 NPs conjugated OFLX molecules generated more inhibitory effects on
the growth of bacteria in both strains. Those results all implied the sizedependent inhibitory effects of AgMUNH2 NPs conjugated OFLX molecules on
the growth of gram-negative bacteria, P. aeruginosa.
We also found that the drug deficient AgMUNH2 groups did little impact on
the cell survivals compared to their counterparts with drug conjugated at the
same concentrations, which implied that AgMUNH2 NPs posed little toxic or
antimicrobial effects when Ag NPs were coated with extra MUNH2 groups on
their surfaces, though several reports have shown the antibacterial effects of
pure silver NPs [150, 152], In addition, our results indicated that toxic effects of
silver NPs could be effectively circumvented when other chemical groups are
coated on their surfaces, which is very important for future application of silver
NPs as effective drug carriers for specifically targeting and treating diseased
areas without harming the surrounding health cells.
Besides, we can also see that as the size of silver NPs increases, it also
leads to higher antimicrobial effects since MIC values of conjugated OFLX

in

PA01 cells decreased from > 2.16 uM (2.4 nm AgMUNH2-OFLX NPs) to 1.08 uM
(13.0 nm AgMUNH2-OFLX NPs), and to 0.6 nM (92.6 nm AgMUNH2-OFLX NPs )
(Table 5, Fig. 34A).
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(A) OFLX alone group, tubes (a-i) represent different concentrations of OFLX in
each glass tube as 0, 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 pM, respectively. (B) 2.4
nm AgMUNH2-OFLX NPs, the conjugated concentrations of OFLX in tubes (a-h)
are 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 pM, respectively; tube (i) contains 2.16 pM
of 2.4 nm AgMUNH2 control NPs. (C) 13.0 nm AgMUNH2-OFLX NPs. (D) 92.6
nm AgMUNH2-OFLX NPs, the concentrations of OFLX in tubes (Fig. 32C-D, a-i)
are identical to the ones in Fig. 32B, tube (i) also contained the AgMUNH2 control
NPs of 13.0 and 92.6 nm, respectively. For all sized AgMUNH2-OFLX NPs, the
concentration of conjugated OFLX is calculated based on the concentration of
AgMUNH2-OFLX NPs solution and the conjugation ratio of OFLX to that sized
AgMUNH2 NPs

Fig. 33 Images of glass tubes showing MIC study of OFLX in AMexA,BOprM cells.
(A) OFLX alone group, glass tubes (a-i) represent different concentrations of
OFLX in each tube as 0, 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, 0.27 pM, respectively.
(B) 2.4 nm AgMUNH2-OFLX NPs, the conjugated concentrations of OFLX in
tubes (a-h) are 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, 0.27 pM, respectively; tube (i)
contains 0.27 pM of 2.4 nm AgMUNH2 control NPs. (C) 13.0 nm AgMUNH2OFLX NPs. (D) 92.6 nm AgMUNH2-OFLX NPs, the concentrations of OFLX in
tubes (Fig. 33C-D, a-i) are identical to the ones in Fig. 33B, tube (i) also
contained the AgMUNH2 control NPs of 13.0 and 92.6 nm, respectively. The
concentrations of conjugated OFLX for all sized AgMUNH2-OFLX NPs are
calculated using the same approaches as described in Fig. 32
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the end of MIC experiment; (a) 2.4 nm AgMUNH2, (b) 13.0 nm AgMUNH2) (c)
92.6 nm AgMUNH2, (d) 2.4 nm AgMUNH2-OFLX, (e) OFLX alone, (f) 13.0 nm
AgMUNH2-OFLX and (g) 92.6 nm AgMUNH2-OFLX. Error bars represent the
standard deviations from three repeated experiments for each sample

117
Table 5 MICs of AgMUNH2 NPs conjugated OFLX in PA01 and AMexA,BOprM cells
MICs of conjugated OFLX in AgMUNHzAgMUNH2OFLX NPs (pM)

Reference

OFLX types
PAOl

AMexA,B-OprM

2.4 nm

>2.16

>0.27

13.0 nm

1.08

0.14

92.6 nm

0.6

0.06

OFLX alone

2.16

0.27

[13]

The results from MIC studies in the AMexA,B-OprM strain (Table 5, Fig.
34B) showed the similar trend as seen in wide type PA01 strain. First, drug free
AgMUNH2 NPs of three sizes had little or no antibacterial effects. Secondly, drug
conjugated AgMUNH2-OFLX NPs exhibited antibacterial effects as a function of
size of AgMUNH2 NPs.
For example, as the size of AgMUNH2 NPs increased from 2.4 nm to 13. 0
nm, and to 92.6 nm, the MICs of OFLX for these different sized AgMUNH^OFLX
NPs in AMexA,B-OprM strain were decreased from > 0.27 pM to 0.14 pM and to
0.06 pM, respectively.

From these results, we found that 2.4 nm AgMUNH2-

OFLX NPs are probably the most biocompatible NPs since their MIC values are
close to those in the OFLX drug alone group for both strains while the other two
sized AgMUNH2-OFLX (13.0 nm and 92.6 nm) can generate more antimicrobial
effects when they are conjugated with drugs.
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Those interesting results not only confirm the existence of enhanced
antimicrobial effects of the drug (OFLX) conjugated silver NPs but also suggest
those effects are largely dependent on the size of NP carriers. As the size of
particles increases, their surface areas also tremendously enlarge which made it
possible for conjugating larger number of drug molecules to single particle.
These particles with higher conjugation ratios of drug molecules will offer greater
advantages over those with lower conjugation ratios for targeting and binding
with specific biological molecules and conferring the potent effects of loaded
drugs. These phenomena have been observed in many previous studies [33, 35,
40, 147, 149], For example, Burygin et al. found enhanced antibacterial activity
of antibiotics mixed with gold NPs [40] and Bhattacharya et al. found that gold
NPs conjugated drugs showed greater bactericidal activity and reduced MIC
compared to their respective free forms [35]. Though these studies observed the
enhanced antimicrobial effects from drug or antibiotics conjugated NPs, it
remains unanswered about the exact mechanisms governing these enhanced
antibacterial effects.

SUMMARY
In this study, we have successfully synthesized three sized silver NPs (2.4
± 0.7, 13.0 ±3.1 and 92.6 ± 4.4 nm) and conjugated them with antibiotic (OFLX).
We also modified the regular LB medium and found that different P. aeruginosa
strains cultured in modified LB medium can still maintain their original efflux
functions as compared with those cultured in regular LB medium without
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significant changes in terms of cell function and cell viability.

Next, we found

size-dependent

different

antimicrobial

effects

generated

by

these

sized

AgMUNH 2 -OFLX NPs in one of gram-negative, clinically important bacteria, P.
aeruginosa, with larger sized AgMUNH2-OFLX (92.6 nm) NPS showing the
highest bactericidal effects, followed by a middle sized AgMUNH2-OFLX (13.0
nm) and finally the smallest sized AgMUNH2-OFLX (2.4 nm) which result is quite
similar to that of the antibiotic alone group. These results indicate that 2.4 nm
silver NPs are probably the most biocompatible silver NPs for sensing and
imaging bio-molecules while the other bigger sized silver NPs, due to their higher
efficiency of antibacterial effects, can be used as efficient drug carriers in the
treatment of many diseases.
In summary, our studies clearly showed the existence of size-dependent
antibacterial effects of AgMUNH2 NPs conjugated OFLX and these important
findings will aid in the application of nano-materials conjugated with different
types of drugs for cancer therapy in the future.

METHODS
Reagents and supplies
Silver perchlorate monohydrate
dihydrate

(99%,

Sigma),

(99%, Alfa Aesar),

2-mercaptoethanol

(99%,

sodium citrate

Sigma),

11-amino-1-

undecanethiol hydrochloride (MUNH2, 99%, Sigma) and sodium borohydride
(98%, Sigma) were used, as received, for synthesis of Ag NPs. Live/dead
bacLight viability and counting assay were purchased from Invitrogen; all other
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reagents
Aldrich.

like LB powder, ofloxacin (OFLX), were purchased from Sigm a1-Ethyl-3-[3-dimethylaminopropyl]-carbodiimide

hydrochloride

(EDC,

99%) and N-hydroxysulfosuccinimide (s-NHS, 98.5%) were from Pierce.

Synthesis and characterization of different sized silver (Ag) nanoparticles
Three different sized Ag NPs (2.4 ± 0.7 nm, 13.0 ±3.1 nm and 92.6 ± 4.4
nm) were synthesized and purified as described previously [38, 42, 43]. Briefly,
for the synthesis of 2.4 ± 0.7 nm Ag NPs, 0.11 mM of AgN 0 3 , 1.91 mM of sodium
citrate, 0.052 mM of PVP, and 25.0 mM of H20 2 in nanopure water (42.3 mL)
were prepared freshly, mixed and stirred constantly. Then, we added NaBH4
(150 pL, 100 mM) into the mixture, the solution color turned to light yellow. After
stirring for another 3 h, the solution was then filtered using 0.2 pm membrane
filters (Whatman). For the synthesis of 13.0 ± 3.1 nm Ag NPs, AgCI04 (2.5 mL,
10 mM, ice-cold) was added into the stirring mixture (247.5 mL) of ice-cold
sodium citrate (3 mM) and NaBH4 (10 mM), and the mixture was stirred at room
temperature for additional 4 h. The solution was then filtered using 0.22 pm filters
(Whatman) and washed twice with nanopure Dl water using ultracentrifugation at
15000 RCF (relative centrifugal force), to prepare stable and purified Ag NPs. For
the synthesis of 92.6 ± 4.4 nm Ag NPs, we added sodium citrate (34 mM, 10mL)
into a refluxing (100 °C) stirring aqueous solution of AgN03 (3.98 mM, 500 mL)
and stirred it for 35 min. Then, we stopped stirring and heating the mixture and
allowed it to cool to room temperature. We added additional sodium citrate (2.5
mM) to further stabilize the NPs in solution. The solution was then filtered via
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0.22 pm filters and washed three times using

nanopure Dl water via

centrifugation. The purified Ag NPs were dispersed in the PBS buffer (0.5 mM
phosphate buffer, 1,5 mM NaCI, pH=7.0). The sizes of single NPs were
determined using high-resolution transmission electron microscopy (HRTEM)
(FEI Tecnai G2 F30 FEG).

The concentrations of NPs were measured and

calculated, as described previously [38, 42, 43]. Plasmonic absorption and
scattering

properties

of bulk

NPs were

characterized

using

UV-visible

spectrometry (Hitachi).

Conjugation of ofloxacin (OFLX) to AgMUNH2 NPs and calculation of
conjugation ratios of drug molecules to AgMUNH2 NPs
1 mL 100 mM MUNH2 in ethanol was added to 100 mL freshly prepared
Ag NPs of three different sizes (2.4 ± 0.7, 13.0 ± 3.1 and 92.6 ± 4.4 nm),
respectively. The mixtures were stirred for 24 h to attach MUNH2 onto the surface
of NPs via their interaction of thiol groups with NPs. The AgMUNH2 NPs were
washed twice by nanopure water to remove excess MUNH2 using centrifugation
(Beckman Optima L90k), 30k rpm (60 min) for 2.4 ± 0.7 nm AgMUNH2, 12k rpm
(90 min) for 13.0 ± 3.1 nm AgMUNH2 and 2.5k rpm (20 min) for 92.6 ± 4.4 nm
AgMUNH2 at 4 °C. The AgMUNH2 NPs were immediately characterized using
UV-visible

spectroscopy,

dark-field

optical

microscopy

and

spectroscopy

(DFOMS), and dynamic light scattering (DLS). The amine groups of AgMUNH2
NPs were conjugated to the carboxyl group of OFLX via peptide bonds using
EDO and s-NHS as mediators. OFLX was first dissolved in 0.5 M HCI and then
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diluted to 10 mM by MES buffer (pH 5.0, 50mM). EDC (30 pmol) and s-NHS (150
pmol) were added to OFLX (3 mL, 50 mM), forming OFLX-s-NHS esters. After
stirring at room temperature for 40 min, the reaction was stopped by adding 10 pi
2-mercaptoethanol. Then, 1 mL OFLX-s-NHS esters was added to 100 mL Ag
MUNH2 NPs of three different sizes, respectively. The solutions were mixed
using a rotary shaker at room temperature for 3 h. The final products (AgMUNH2OFLX NPs of three different sizes) were washed using centrifugation, 30k rpm
(60 min) for 2.4 nm AgMUNH2-OFLX, 12k rpm (90 min) for 13.0 nm Ag MUNH2OFLX and 2.5k rpm (20 min) for 92.6 nm Ag MUNH2-OFLX. The purified
AgMUNH2-OFLX NPs were resuspended in 50 mM PBS (pH 7.0) and stored at 4
°C for the future use. The sizes and optical properties of AgMUNH2-OFLX NPs
were characterized using DLS, UV-visible spectra and DFOMS.
Conjugation ratios of drug (OFLX) to each of three sized AgMUNH2 NPs
were calculated as described below. First, a standard curve was generated by
measuring the absorbance value (A) at peak wavelength (A = 288 nm) from the
absorption UV-visible spectra for different concentrations of OFLX alone
solutions to calculate the absorption coefficient (e). Next, to get the absorbance
scale for each sized AgMUNH^OFLX NPs, we divided the absorbance value at A
= 288 nm by corresponding height (mm) from the UV-visible spectra of each
sized AgMUNH2-OFLX solution at stock concentration (50 nM for 2.4 nm, 3.3 nM
for 13.0 nm and 0.02975 nM for 92.6 nm AgMUNH2-OFLX NPs, respectively).
After that, we calculated the net height (cm) of absorbance at 288 nm
corresponding to the part of conjugated OFLX by subtracting the height a=288 nm
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from spectra of AgM UNfVOFLX solution to the height a= 288 nm from spectra of
AgMUNH 2 solution alone. Then, we got the concentrations of conjugated OFLX
for each sized AgMUNH2-OFLX NPs from each value of absorbance scale timing
net height of absorbance for conjugated OFLX part. Finally the conjugation ratio
for each sized AgMUNH 2 -OFLX NPs is calculated by dividing the concentration
of conjugated OFLX to its stock concentration of AgMUNH2-OFLX solution,
respectively.

Stability study of AgMUNH2-OFLX NPs in modified LB medium
Studies of stability of AgMUNH2-OFLX NPs in modified LB medium were
done by monitoring the UV-visible spectra changes and directly countering the
average, number of NPs from 10 images by DFOMS on a slide prepared from the
solution containing each sized AgMUNH2-OFLX NPs in modified LB medium at
four different time points over 24 h of incubation. The concentration used for
each sized AgMUNH2-OFLX NPs in those stability studies is much higher than
required for the later MIC experiment according to previous MIC studies of OFLX
alone in different P. aeruginosa strains [13]. All experiments have been repeated
at least three times.

Cell function and viability assay in modified LB medium
To investigate if the cell functions have changed or not in the modified LB
medium, we studied the efflux functions of different P. aeruginosa strains (wide
type PA01, NalB with efflux pump overexpressed and AMexA,B-OprM with
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MexA,B-OprM pump deleted). A single colony from freshly streaked plates for
each of three strains were inoculated into 15 mL regular and modified LB
medium and cultured with vigorous shaking (200 rpm, 37 °C). Samples were
taken out for measuring the optical density (ODeoo nm ) every 30 min up to 12 hrs
of culture. Time course incorporation of ethidium bromide (EtBr, 10 pM) in the
above P. aeruginosa strains were monitored over a two-hour period on a
fluorescence spectrometer. The excitation and emission wavelength were set at
465 and 600 nm with a slit of 10 and 10 nm width, respectively.
Cell viability assay were done according to the manufacture’s instruction
(Bac Live / Dead viability assay from Invitrogen). The percentage of live and
dead cells were calculated

from multiple images of both Dark Field and the

corresponding Green / Red fluorescence images for over 500 cells in total for
each strain used.

Study of MIC of OFLX in different P. aeruginosa strains
To investigate the antibacterial effects of silver NPs with or without drug
molecule (OFLX) conjugated, we directly measured the MICs of OFLX in different
P. aeruginosa strains for those different sized AgMUNH2-OFLX NPs. For either
PA01 or AMexA,B-OprM strain used here, about 104 cells from a pre-culture
solution were inoculated into the modified LB medium containing a set of different
concentrations of OFLX (concentrations of corresponding OFLX for three sized
AgMUNH2-OFLX

NPs are calculated

based

on

their conjugation

ratios,

respectively; AgMUNH 2 NPs of each size and OFLX alone were used as

controls). Cells are cultured in a 15 mL test tube (4 mL volume in total) with
vigorous shaking (200 rpm, 37 °C) for about 18 hrs, samples were taken out at
different time points (T
density

( O D 6oo nm)-

( O D 6oo nm)

6

h, T 12h and T 18h) for measuring the values of optical

Results of MIC studies were plotted with Optical density

values versus the concentrations of conjugated OFLX molecules

calculated from the conjugation ratio of each sized NPs and the concentration of
nanoparticle solution and results shown are only for samples at T18h.
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CHAPTER VI
CONCLUSION

In summary, this dissertation presents structural and functional studies of
multidrug membrane transporters using molecular biology approaches, structural
modeling, cutting-edge single NP plasmonic spectroscopy and dark-field optical
microscopy and spectroscopy. Two representative MDR transporters, ABC (ATPbinding cassette, BmrA) and RND (resistance-nodulation-cell division, MexA.BOprM)

in gram-positive and gram-negative

bacteria (B. subtilis and P.

aeruginosa), are studied in real-time at single cell resolution.
In Chapter II, we fused EGFP with the N-terminus or C-terminus of BmrA
to construct BmrA-EGFP fusion proteins and characterized their efflux functions
in four strains of B. subtilis cells (Nt-BmrA-EGFP, Ct-BmrA-EGFP, BmrA, and
ABmrA, B. subtilis) using fluorescence microscopy and spectroscopy. Fusion of
ABC membrane transporters with EGFP offers the opportunity to visualize
membrane transporters and study their interactions with substrates that lead to
their translocations. Note that the fusion of ABC transporters with EGFP (BmrAEGFP) may alter their efflux functions. Therefore, it is very crucial that we first
characterize heir efflux functions prior to using them to probe molecular
mechanisms of membrane transporters. The results show that BmrA-EGFP
fusion proteins exhibit the similar efflux kinetics of BmrA and retain the efflux
functions of BmrA.

Modeled structures of the fusion proteins show a highly

127
flexible linker region connecting EGFP with BmrA, suggesting a minimal
obstruction of EGFP to the BmrA.
In Chapter III, we studied the size-dependent efflux functions of BmrAEGFP and BmrA using single plasmonic nanoparticle imaging probes and
spectroscopy, and found size-dependent efflux kinetics of BmrA transporter.
These two new stains of BmrA-EGFP offer the possibility for one to visualize
BmrA transporter and study efflux function and mechanisms of BmrA.
In Chapter IV, using the similar approaches, we fused EGFP with MexB
(subunit of MexA,B-OprM transporter) and characterized efflux functions of fusion
protein (MexA-EGFP-MexB-OprM) using fluorescence spectroscopy. The results
show that the EGFP fusion strain only partially retains the original efflux functions
of MexA,B-OprM transporter. Structural analysis of fusion protein suggests
possible steric hindrance of EGFP towards the conformational arrangements of
MexA,B-OprM tripartite proteins, which led to the steric effect upon their efflux
functions.
In Chapter V, we further functionalized Ag NPs with the antibiotic
(ofloxacin), which is a representative substrate of MexA,B-OprM transporter in P.
aeruginosa. We studied the antibacterial effects of ofloxacin alone (absence of
the NPs), and various sized Ag NPs conjugated with ofloxacin. We found that the
larger sized Ag NPs conjugated ofloxacin showed the lower MICs and higher
inhibitory potency towards the bacterial growth in P. aeruginosa.
In summary, we have studied the structures and functions of two different
types of MDR efflux pumps (ABC and RND) in both gram negative and gram

128
positive bacteria using fluorescence microscopy and spectroscopy, and single
plasmonic microscopy and spectroscopy. The results offer new insights into the
structural and functional studies of multidrug membrane transporters (efflux
pumps), and have demonstrated the power of integrating new nanotechnology
approaches with molecular biology techniques for better understanding of MDR.
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